Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:dihydroxy-5beta-cholanic acid
go back to main search page
Accession:CHEBI:23775 term browser browse the term
Definition:A hydroxy-5beta-cholanic acid carrying two hydroxy groups at unspecified positions.
Synonyms:related_synonym: Formula=C24H40O4;   dihydroxy-5beta-cholanic acids


show annotations for term's descendants           Sort by:
 
chenodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP-binding cassette, sub-family B (MDR/TAP), member 11 multiple interactions
increases expression
decreases expression
ISO
EXP
7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA; [pregna-4,17-diene-3,16-dione co-treated with Chenodeoxycholic Acid] results in increased expression of ABCB11 mRNA; Copper Sulfate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; LG 100268 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; Zinc Sulfate inhibits the reaction [Copper Sulfate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]]
Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA]]
Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA; Chenodeoxycholic Acid results in increased expression of ABCB11 protein
Chenodeoxycholic Acid results in decreased expression of ABCB11 mRNA
epiallopregnanolone sulfate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]
CTD PMID:12519787, PMID:12525500, PMID:14684751, PMID:16423920, PMID:17963371, PMID:19072826, PMID:22178739, PMID:22291955, PMID:22961653, PMID:25055961, PMID:25582706, PMID:26241054, PMID:27174168, PMID:27743861, PMID:32152650, PMID:32294204 NCBI chr 2:69,238,282...69,342,616
Ensembl chr 2:69,238,282...69,342,616
JBrowse link
G Abcb4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 multiple interactions
increases expression
ISO
EXP
[[Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which binds to ABCB4 promoter] which results in increased expression of ABCB4 mRNA; [Bezafibrate co-treated with Chenodeoxycholic Acid] results in increased expression of ABCB4 mRNA
[Chenodeoxycholic Acid co-treated with Ketoconazole] results in increased expression of ABCB4 mRNA
Chenodeoxycholic Acid results in increased expression of ABCB4 mRNA
CTD PMID:14527955, PMID:14623915, PMID:15588777, PMID:25582706, PMID:27174168, PMID:30985903 NCBI chr 5:8,893,614...8,959,226
Ensembl chr 5:8,893,717...8,959,231
JBrowse link
G Abcc1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr16:14,361,453...14,474,878
Ensembl chr16:14,361,558...14,475,737
JBrowse link
G Abcc2 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 multiple interactions
increases expression
affects expression
ISO
EXP
ABCC2 protein affects the reaction [verlukast results in decreased secretion of Chenodeoxycholic Acid]; Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA]]
Chenodeoxycholic Acid results in increased expression of ABCC2 mRNA
Chenodeoxycholic Acid affects the expression of ABCC2 mRNA
CTD PMID:20888898, PMID:21262925, PMID:25055961, PMID:25582706, PMID:27743861 NCBI chr19:43,782,308...43,838,332
Ensembl chr19:43,782,192...43,840,740
JBrowse link
G Abcc3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 increases expression
multiple interactions
ISO
EXP
Chenodeoxycholic Acid results in increased expression of ABCC3 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA
CTD PMID:20888898, PMID:25055961, PMID:25582706, PMID:27743861, PMID:32152650 NCBI chr11:94,343,295...94,393,017
Ensembl chr11:94,343,295...94,392,997
JBrowse link
G Abcc4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 multiple interactions
decreases expression
ISO 7-hydroxytheonellasterol inhibits the reaction [[Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]] which results in decreased expression of ABCC4 mRNA]; 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]]; 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid results in decreased expression of ABCC4 mRNA]; [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]] which results in decreased expression of ABCC4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter] CTD PMID:22291955, PMID:32152650 NCBI chr14:118,482,692...118,707,856
Ensembl chr14:118,482,692...118,706,219
JBrowse link
G Abcg5 ATP binding cassette subfamily G member 5 increases expression ISO
EXP
Chenodeoxycholic Acid results in increased expression of ABCG5 mRNA CTD PMID:25055961, PMID:25582706, PMID:27174168 NCBI chr17:84,658,174...84,683,011
Ensembl chr17:84,658,234...84,683,011
JBrowse link
G Abcg8 ATP binding cassette subfamily G member 8 increases expression EXP
ISO
Chenodeoxycholic Acid results in increased expression of ABCG8 mRNA CTD PMID:25582706, PMID:27174168 NCBI chr17:84,676,302...84,700,333
Ensembl chr17:84,676,302...84,700,333
JBrowse link
G Acaca acetyl-Coenzyme A carboxylase alpha multiple interactions EXP Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ACACA protein] CTD PMID:27773935 NCBI chr11:84,129,635...84,401,651
Ensembl chr11:84,129,672...84,401,651
JBrowse link
G Acad11 acyl-Coenzyme A dehydrogenase family, member 11 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of ACAD11 mRNA CTD PMID:27174168 NCBI chr 9:104,063,724...104,127,656
Ensembl chr 9:104,063,377...104,127,725
JBrowse link
G Acads acyl-Coenzyme A dehydrogenase, short chain multiple interactions EXP Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of ACADS mRNA] CTD PMID:27773935 NCBI chr 5:115,110,299...115,119,346
Ensembl chr 5:115,110,299...115,119,346
JBrowse link
G Acadsb acyl-Coenzyme A dehydrogenase, short/branched chain decreases expression ISO Chenodeoxycholic Acid results in decreased expression of ACADSB mRNA CTD PMID:27174168 NCBI chr 7:131,410,601...131,446,211
Ensembl chr 7:131,410,601...131,448,944
JBrowse link
G Acat1 acetyl-Coenzyme A acetyltransferase 1 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of ACAT1 mRNA CTD PMID:27174168 NCBI chr 9:53,580,522...53,610,350
Ensembl chr 9:53,580,522...53,610,382
JBrowse link
G Acta2 actin, alpha 2, smooth muscle, aorta multiple interactions EXP Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ACTA2 mRNA] CTD PMID:27773935 NCBI chr19:34,240,336...34,255,585
Ensembl chr19:34,241,090...34,255,590
JBrowse link
G Ahr aryl-hydrocarbon receptor decreases expression
increases secretion
multiple interactions
ISO
EXP
Chenodeoxycholic Acid results in decreased expression of AHR mRNA
AHR gene mutant form results in increased secretion of Chenodeoxycholic Acid
[AHR gene mutant form affects the susceptibility to Tetrachlorodibenzodioxin] which results in decreased secretion of Chenodeoxycholic Acid
CTD PMID:27174168, PMID:29452137, PMID:32679164 NCBI chr12:35,497,979...35,534,989
Ensembl chr12:35,497,974...35,535,038
JBrowse link
G Akr1a1 aldo-keto reductase family 1, member A1 (aldehyde reductase) multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 4:116,636,510...116,651,674
Ensembl chr 4:116,636,510...116,651,680
JBrowse link
G Akr1c21 aldo-keto reductase family 1, member C21 decreases activity
affects binding
ISO Chenodeoxycholic Acid results in decreased activity of AKR1C2 protein
Chenodeoxycholic Acid binds to AKR1C2 protein
CTD PMID:8486699, PMID:8573067 NCBI chr13:4,574,075...4,586,543
Ensembl chr13:4,574,075...4,586,541
JBrowse link
G Akr1c6 aldo-keto reductase family 1, member C6 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of AKR1C4 mRNA CTD PMID:27174168 NCBI chr13:4,434,311...4,457,530
Ensembl chr13:4,434,306...4,457,877
JBrowse link
G Akr7a5 aldo-keto reductase family 7, member A5 (aflatoxin aldehyde reductase) multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 NCBI chr 4:139,310,720...139,318,786
Ensembl chr 4:139,310,744...139,318,426
JBrowse link
G Angptl3 angiopoietin-like 3 decreases expression
multiple interactions
ISO
EXP
Chenodeoxycholic Acid results in decreased expression of ANGPTL3 mRNA
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ANGPTL3 mRNA]
CTD PMID:27174168, PMID:27773935 NCBI chr 4:99,030,954...99,038,192
Ensembl chr 4:99,030,954...99,046,111
JBrowse link
G Aox1 aldehyde oxidase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 1:58,029,809...58,106,410
Ensembl chr 1:58,029,931...58,106,413
JBrowse link
G Apoa1 apolipoprotein A-I decreases expression ISO Chenodeoxycholic Acid results in decreased expression of APOA1 protein CTD PMID:19445040 NCBI chr 9:46,228,630...46,230,469
Ensembl chr 9:46,228,580...46,230,466
JBrowse link
G Apoa4 apolipoprotein A-IV decreases expression ISO Chenodeoxycholic Acid results in decreased expression of APOA4 mRNA CTD PMID:27174168 NCBI chr 9:46,240,844...46,243,458
Ensembl chr 9:46,240,696...46,243,459
JBrowse link
G Apoc2 apolipoprotein C-II multiple interactions EXP Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of APOC2 mRNA] CTD PMID:27773935 NCBI chr 7:19,671,579...19,677,941
Ensembl chr 7:19,671,579...19,677,941
JBrowse link
G Apoc3 apolipoprotein C-III multiple interactions EXP Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of APOC3 mRNA] CTD PMID:27773935 NCBI chr 9:46,233,050...46,235,636
Ensembl chr 9:46,232,933...46,235,636
JBrowse link
G Apoc4 apolipoprotein C-IV decreases expression ISO Chenodeoxycholic Acid results in decreased expression of APOC4 mRNA CTD PMID:27174168 NCBI chr 7:19,678,084...19,681,460
Ensembl chr 7:19,678,083...19,681,479
JBrowse link
G Apoh apolipoprotein H decreases expression ISO Chenodeoxycholic Acid results in decreased expression of APOH mRNA CTD PMID:27174168 NCBI chr11:108,395,297...108,414,396
Ensembl chr11:108,343,354...108,414,396
JBrowse link
G Apom apolipoprotein M decreases expression ISO Chenodeoxycholic Acid results in decreased expression of APOM mRNA CTD PMID:27174168 NCBI chr17:35,128,997...35,131,801
Ensembl chr17:35,128,997...35,132,050
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr15:80,255,184...80,257,545
Ensembl chr15:80,255,184...80,257,541
JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr 1:170,704,457...170,868,585
Ensembl chr 1:170,704,674...170,867,771
JBrowse link
G Atg7 autophagy related 7 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 6:114,643,127...114,860,604
Ensembl chr 6:114,643,097...114,860,614
JBrowse link
G Baat bile acid-Coenzyme A: amino acid N-acyltransferase decreases expression ISO Chenodeoxycholic Acid results in decreased expression of BAAT mRNA CTD PMID:27174168 NCBI chr 4:49,489,416...49,507,915
Ensembl chr 4:49,489,422...49,506,557
JBrowse link
G Bax BCL2-associated X protein increases expression ISO Chenodeoxycholic Acid results in increased expression of BAX mRNA CTD PMID:17881359 NCBI chr 7:45,461,695...45,466,903
Ensembl chr 7:45,461,697...45,466,898
JBrowse link
G Casp3 caspase 3 increases activity
multiple interactions
ISO Chenodeoxycholic Acid results in increased activity of CASP3 protein
Chenodeoxycholic Acid results in increased cleavage of and results in increased activity of CASP3 protein
CTD PMID:16573382, PMID:19054763 NCBI chr 8:46,617,291...46,639,698
Ensembl chr 8:46,617,291...46,639,689
JBrowse link
G Casp9 caspase 9 multiple interactions
increases activity
ISO [Chenodeoxycholic Acid co-treated with tauroursodeoxycholic acid] results in increased activity of CASP9 protein; Chenodeoxycholic Acid results in increased cleavage of and results in increased activity of CASP9 protein
Chenodeoxycholic Acid results in increased activity of CASP9 protein
CTD PMID:14976352, PMID:19054763 NCBI chr 4:141,793,612...141,815,978
Ensembl chr 4:141,793,612...141,815,976
JBrowse link
G Cat catalase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 NCBI chr 2:103,453,904...103,485,153
Ensembl chr 2:103,453,849...103,485,160
JBrowse link
G Cbr1 carbonyl reductase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr16:93,607,837...93,610,349
Ensembl chr16:93,605,853...93,610,505
JBrowse link
G Ccl2 chemokine (C-C motif) ligand 2 increases expression
multiple interactions
EXP Chenodeoxycholic Acid results in increased expression of CCL2 mRNA
Chenodeoxycholic Acid affects the reaction [alisol A 24-acetate inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of CCL2 mRNA]]; Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CCL2 mRNA]; EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CCL2 mRNA]
CTD PMID:21224055, PMID:27773935, PMID:29883724 NCBI chr11:82,035,577...82,037,452
Ensembl chr11:82,035,571...82,037,453
JBrowse link
G Ccl20 chemokine (C-C motif) ligand 20 increases expression EXP Chenodeoxycholic Acid results in increased expression of CCL20 mRNA CTD PMID:21224055 NCBI chr 1:83,116,766...83,119,167
Ensembl chr 1:83,116,766...83,119,167
JBrowse link
G Ccl3 chemokine (C-C motif) ligand 3 increases expression EXP Chenodeoxycholic Acid results in increased expression of CCL3 mRNA CTD PMID:21224055 NCBI chr11:83,647,843...83,649,378
Ensembl chr11:83,647,844...83,649,355
JBrowse link
G Ccl5 chemokine (C-C motif) ligand 5 multiple interactions
increases expression
ISO
EXP
Bezafibrate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of CCL5 mRNA]; Bezafibrate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of CCL5 protein]; Fenofibrate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of CCL5 mRNA]; Fenofibrate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of CCL5 protein]
Chenodeoxycholic Acid results in increased expression of CCL5 mRNA; Chenodeoxycholic Acid results in increased expression of CCL5 protein
CTD PMID:12126966, PMID:21224055 NCBI chr11:83,525,778...83,530,518
Ensembl chr11:83,525,778...83,530,518
JBrowse link
G Ccl7 chemokine (C-C motif) ligand 7 multiple interactions
increases expression
EXP EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CCL7 mRNA] CTD PMID:21224055 NCBI chr11:82,045,712...82,047,525
Ensembl chr11:82,045,712...82,047,525
JBrowse link
G Ccr2 chemokine (C-C motif) receptor 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650 NCBI chr 9:124,101,918...124,109,140
Ensembl chr 9:124,101,950...124,113,557
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B affects localization ISO Chenodeoxycholic Acid affects the localization of CDKN1B protein CTD PMID:20818264 NCBI chr 6:134,920,401...134,925,525
Ensembl chr 6:134,920,401...134,925,513
JBrowse link
G Cdx2 caudal type homeobox 2 increases expression ISO Chenodeoxycholic Acid results in increased expression of CDX2 mRNA CTD PMID:20818264 NCBI chr 5:147,300,900...147,307,249
Ensembl chr 5:147,300,805...147,307,270
JBrowse link
G Col1a1 collagen, type I, alpha 1 decreases expression
multiple interactions
ISO
EXP
Chenodeoxycholic Acid results in decreased expression of COL1A1 mRNA
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of COL1A1 mRNA]
CTD PMID:15980055, PMID:27773935 NCBI chr11:94,936,224...94,953,042
Ensembl chr11:94,936,224...94,953,042
JBrowse link
G Col1a2 collagen, type I, alpha 2 multiple interactions EXP Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of COL1A2 mRNA] CTD PMID:27773935 NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544
JBrowse link
G Coro1a coronin, actin binding protein 1A multiple interactions
decreases expression
ISO [Chenodeoxycholic Acid co-treated with Tretinoin] results in decreased expression of CORO1A mRNA
Chenodeoxycholic Acid results in decreased expression of CORO1A mRNA
CTD PMID:16040207 NCBI chr 7:126,699,774...126,704,816
Ensembl chr 7:126,699,773...126,707,787
JBrowse link
G Cpt1a carnitine palmitoyltransferase 1a, liver multiple interactions EXP Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of CPT1A mRNA] CTD PMID:27773935 NCBI chr19:3,322,326...3,385,735
Ensembl chr19:3,322,334...3,385,733
JBrowse link
G Csf1 colony stimulating factor 1 (macrophage) multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 NCBI chr 3:107,741,048...107,760,469
Ensembl chr 3:107,741,048...107,760,469
JBrowse link
G Csf2 colony stimulating factor 2 (granulocyte-macrophage) multiple interactions
increases expression
EXP EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CSF2 mRNA] CTD PMID:21224055 NCBI chr11:54,247,270...54,249,899
Ensembl chr11:54,247,271...54,249,667
JBrowse link
G Csf3 colony stimulating factor 3 (granulocyte) increases expression EXP Chenodeoxycholic Acid results in increased expression of CSF3 mRNA CTD PMID:21224055 NCBI chr11:98,700,183...98,703,631
Ensembl chr11:98,701,263...98,703,629
JBrowse link
G Cth cystathionase (cystathionine gamma-lyase) multiple interactions ISO chenodeoxycholic acid inhibits the reaction [Carbon Tetrachloride decreases expression and activity of cystathionine gamma-lyase in rat liver] RGD PMID:19418582 RGD:15042868 NCBI chr 3:157,894,248...157,925,081
Ensembl chr 3:157,894,248...157,925,077
JBrowse link
G Cxcl10 chemokine (C-X-C motif) ligand 10 increases expression EXP Chenodeoxycholic Acid results in increased expression of CXCL10 mRNA CTD PMID:21224055 NCBI chr 5:92,346,638...92,348,889
Ensembl chr 5:92,346,638...92,348,889
JBrowse link
G Cxcl11 chemokine (C-X-C motif) ligand 11 increases expression EXP Chenodeoxycholic Acid results in increased expression of CXCL11 mRNA CTD PMID:21224055 NCBI chr 5:92,359,544...92,363,296
Ensembl chr 5:92,359,544...92,365,485
JBrowse link
G Cxcl16 chemokine (C-X-C motif) ligand 16 increases expression EXP Chenodeoxycholic Acid results in increased expression of CXCL16 mRNA CTD PMID:21224055 NCBI chr11:70,454,389...70,459,984
Ensembl chr11:70,453,983...70,459,984
JBrowse link
G Cxcl2 chemokine (C-X-C motif) ligand 2 increases expression
multiple interactions
EXP Chenodeoxycholic Acid results in increased expression of CXCL2 mRNA; Chenodeoxycholic Acid results in increased expression of CXCL2 protein
EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of CXCL2 protein]
CTD PMID:21224055 NCBI chr 5:90,903,899...90,905,938
Ensembl chr 5:90,903,871...90,905,938
JBrowse link
G Cxcl3 chemokine (C-X-C motif) ligand 3 increases expression EXP Chenodeoxycholic Acid results in increased expression of CXCL1 mRNA CTD PMID:21224055 NCBI chr 5:90,786,101...90,788,093
Ensembl chr 5:90,786,103...90,789,600
JBrowse link
G Cyld CYLD lysine 63 deubiquitinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr 8:88,696,878...88,751,946
Ensembl chr 8:88,697,028...88,751,945
JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 decreases expression
multiple interactions
EXP Chenodeoxycholic Acid results in decreased expression of CYP17A1 mRNA
NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in decreased expression of CYP17A1 mRNA]
CTD PMID:22961653 NCBI chr19:46,667,165...46,673,000
Ensembl chr19:46,667,165...46,673,172
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of CYP1A1 mRNA CTD PMID:27174168 NCBI chr 9:57,687,928...57,703,824
Ensembl chr 9:57,687,928...57,703,824
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of CYP1A2 mRNA CTD PMID:27174168 NCBI chr 9:57,676,937...57,683,655
Ensembl chr 9:57,676,937...57,683,703
JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 decreases expression ISO
EXP
Chenodeoxycholic Acid results in decreased expression of CYP27A1 mRNA CTD PMID:7832767, PMID:25582706 NCBI chr 1:74,713,148...74,737,897
Ensembl chr 1:74,713,574...74,737,892
JBrowse link
G Cyp2a22 cytochrome P450, family 2, subfamily a, polypeptide 22 decreases activity ISO Chenodeoxycholic Acid results in decreased activity of CYP2A1 protein CTD PMID:8889968 NCBI chr 7:26,931,631...26,939,413
Ensembl chr 7:26,931,631...26,939,384
JBrowse link
G Cyp2b10 cytochrome P450, family 2, subfamily b, polypeptide 10 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA CTD PMID:32152650 NCBI chr 7:25,897,658...25,926,624
Ensembl chr 7:25,897,620...25,926,624
JBrowse link
G Cyp2c29 cytochrome P450, family 2, subfamily c, polypeptide 29 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of CYP2C8 mRNA CTD PMID:27174168 NCBI chr19:39,287,044...39,330,713
Ensembl chr19:39,269,405...39,330,713
JBrowse link
G Cyp2c52-ps cytochrome P450, family 2, subfamily c, polypeptide 52, pseudogene decreases activity ISO Chenodeoxycholic Acid results in decreased activity of CYP2C11 protein CTD PMID:8889968 NCBI chr19:38,976,662...39,003,627
Ensembl chr19:38,976,647...39,003,289
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of CYP2E1 mRNA CTD PMID:27174168 NCBI chr 7:140,763,819...140,774,990
Ensembl chr 7:140,763,739...140,774,987
JBrowse link
G Cyp3a11 cytochrome P450, family 3, subfamily a, polypeptide 11 decreases expression
multiple interactions
ISO Chenodeoxycholic Acid results in decreased expression of CYP3A4 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; Chenodeoxycholic Acid promotes the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]
CTD PMID:19299527, PMID:27174168, PMID:32152650 NCBI chr 5:145,854,607...145,879,854
Ensembl chr 5:145,854,426...145,879,964
JBrowse link
G Cyp7a1 cytochrome P450, family 7, subfamily a, polypeptide 1 multiple interactions
decreases expression
EXP
ISO
NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in decreased expression of CYP7A1 mRNA]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Chenodeoxycholic Acid analog binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA
[Chenodeoxycholic Acid co-treated with Ketoconazole] results in decreased expression of CYP7A1 mRNA; [Chenodeoxycholic Acid results in increased expression of FGF19 protein] which results in decreased expression of CYP7A1 protein
CTD PMID:17963371, PMID:19072826, PMID:20671298, PMID:20835427, PMID:25055961, PMID:25582706, PMID:27174168, PMID:30985903, PMID:32152650 NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633
JBrowse link
G Cyp8b1 cytochrome P450, family 8, subfamily b, polypeptide 1 decreases expression ISO
EXP
Chenodeoxycholic Acid results in decreased expression of CYP8B1 mRNA CTD PMID:25055961, PMID:25582706 NCBI chr 9:121,914,356...121,916,305
Ensembl chr 9:121,914,356...121,916,305
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA CTD PMID:32152650 NCBI chr10:127,290,793...127,296,291
Ensembl chr10:127,290,774...127,296,288
Ensembl chr10:127,290,774...127,296,288
JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr 8:83,608,175...83,612,653
Ensembl chr 8:83,608,193...83,612,653
JBrowse link
G Dnajb11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr16:22,857,845...22,879,634
Ensembl chr16:22,857,845...22,879,634
JBrowse link
G Dnajb6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 5:29,735,898...29,786,478
Ensembl chr 5:29,735,688...29,818,134
JBrowse link
G Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 NCBI chr12:44,205,897...44,210,068
Ensembl chr12:44,205,559...44,210,326
JBrowse link
G Dnajc1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr 2:18,205,634...18,394,099
Ensembl chr 2:18,195,654...18,392,830
JBrowse link
G Dnajc10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 NCBI chr 2:80,315,446...80,354,055
Ensembl chr 2:80,315,466...80,354,043
JBrowse link
G Dnajc16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 4:141,761,998...141,790,644
Ensembl chr 4:141,760,189...141,790,931
JBrowse link
G Dnajc18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 NCBI chr18:35,671,103...35,708,418
Ensembl chr18:35,671,103...35,708,414
JBrowse link
G Dnajc19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 3:34,057,280...34,081,354
Ensembl chr 3:34,056,020...34,081,321
JBrowse link
G Dnajc21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr15:10,446,763...10,470,568
Ensembl chr15:10,446,756...10,470,516
JBrowse link
G Dnajc3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr14:118,937,932...118,981,702
Ensembl chr14:118,937,976...118,981,697
JBrowse link
G Dnajc6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 4:101,496,648...101,642,799
Ensembl chr 4:101,496,631...101,642,799
JBrowse link
G Dnajc9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 NCBI chr14:20,384,638...20,388,910
Ensembl chr14:20,384,638...20,388,910
JBrowse link
G Edn1 endothelin 1 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of EDN1 mRNA CTD PMID:16357303 NCBI chr13:42,301,476...42,307,990
Ensembl chr13:42,301,476...42,307,990
JBrowse link
G Egr1 early growth response 1 multiple interactions
increases expression
EXP EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CCL2 mRNA]; EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CCL7 mRNA]; EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CSF2 mRNA]; EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of SERPINE1 mRNA]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of CXCL2 protein]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 protein]; SL 327 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of EGR1 mRNA]; SL 327 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of EGR1 protein]; U 0126 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of EGR1 mRNA]; U 0126 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of EGR1 protein]
Chenodeoxycholic Acid results in increased expression of EGR1 mRNA; Chenodeoxycholic Acid results in increased expression of EGR1 protein
CTD PMID:19931294, PMID:21224055 NCBI chr18:34,861,207...34,864,956
Ensembl chr18:34,859,823...34,864,984
JBrowse link
G Enc1 ectodermal-neural cortex 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr13:97,241,105...97,253,040
Ensembl chr13:97,241,105...97,253,034
JBrowse link
G Ephx1 epoxide hydrolase 1, microsomal decreases expression
multiple interactions
ISO Chenodeoxycholic Acid results in decreased expression of EPHX1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA
CTD PMID:27174168, PMID:32152650 NCBI chr 1:180,989,556...181,017,569
Ensembl chr 1:180,976,210...181,020,904
JBrowse link
G Fabp6 fatty acid binding protein 6 multiple interactions
increases expression
ISO
EXP
[Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FABP6 mRNA; Ursodeoxycholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased expression of FABP6 mRNA] CTD PMID:15821044, PMID:15935148, PMID:17963371, PMID:25582706 NCBI chr11:43,596,040...43,601,562
Ensembl chr11:43,596,049...43,601,540
JBrowse link
G Fabp7 fatty acid binding protein 7, brain decreases expression ISO Chenodeoxycholic Acid results in decreased expression of FABP7 mRNA CTD PMID:27174168 NCBI chr10:57,784,923...57,788,450
Ensembl chr10:57,784,881...57,788,450
JBrowse link
G Fasn fatty acid synthase multiple interactions EXP Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of FASN protein] CTD PMID:27773935 NCBI chr11:120,805,958...120,825,166
Ensembl chr11:120,805,846...120,824,547
JBrowse link
G Fgf15 fibroblast growth factor 15 increases expression
multiple interactions
ISO
EXP
Chenodeoxycholic Acid results in increased expression of FGF15 mRNA; Chenodeoxycholic Acid results in increased expression of FGF19 protein
Chenodeoxycholic Acid results in increased expression of FGF19 mRNA
[[Chenodeoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Chenodeoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter
[Chenodeoxycholic Acid results in increased expression of FGF19 protein] which results in decreased expression of CYP7A1 protein
CTD PMID:16269825, PMID:17696253, PMID:20835427, PMID:22561792, PMID:25055961, PMID:25582706, PMID:27174168, PMID:29222744 NCBI chr 7:144,896,532...144,900,953
Ensembl chr 7:144,896,531...144,900,953
JBrowse link
G Fkbp5 FK506 binding protein 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr17:28,398,753...28,486,149
Ensembl chr17:28,399,094...28,517,527
JBrowse link
G Fmo1 flavin containing monooxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 NCBI chr 1:162,829,561...162,866,610
Ensembl chr 1:162,829,561...162,866,610
JBrowse link
G Fos FBJ osteosarcoma oncogene multiple interactions ISO Chenodeoxycholic Acid results in increased activity of [JUN protein co-treated with FOS protein] CTD PMID:8631127 NCBI chr12:85,473,890...85,477,274
Ensembl chr12:85,473,890...85,477,273
JBrowse link
G Fosl1 fos-like antigen 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr19:5,447,698...5,455,938
Ensembl chr19:5,447,547...5,455,946
JBrowse link
G Foxm1 forkhead box M1 increases expression
multiple interactions
EXP Chenodeoxycholic Acid results in increased expression of FOXM1 mRNA
NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of FOXM1 mRNA]
CTD PMID:22135065 NCBI chr 6:128,362,994...128,375,886
Ensembl chr 6:128,362,967...128,376,146
JBrowse link
G Ftl1 ferritin light polypeptide 1 multiple interactions ISO [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of FTL mRNA CTD PMID:17724089 NCBI chr 7:45,457,944...45,459,886
Ensembl chr 7:45,457,944...45,459,884
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions
increases expression
ISO [Chenodeoxycholic Acid results in increased expression of GCLC protein] which results in increased abundance of Glutathione CTD PMID:17724089 NCBI chr 9:77,754,535...77,794,489
Ensembl chr 9:77,754,535...77,794,485
JBrowse link
G Gclm glutamate-cysteine ligase, modifier subunit increases expression
multiple interactions
ISO Chenodeoxycholic Acid results in increased expression of GCLM protein
[Chenodeoxycholic Acid results in increased expression of GCLM protein] which results in increased abundance of Glutathione
CTD PMID:17724089 NCBI chr 3:122,245,487...122,267,215
Ensembl chr 3:122,245,557...122,270,732
JBrowse link
G Gpbar1 G protein-coupled bile acid receptor 1 multiple interactions
increases expression
ISO [Chenodeoxycholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; Chenodeoxycholic Acid binds to and results in increased activity of GPBAR1 protein
Chenodeoxycholic Acid results in increased expression of GPBAR1 mRNA
CTD PMID:17963371, PMID:18180267, PMID:25055961 NCBI chr 1:74,278,600...74,279,589
Ensembl chr 1:74,278,550...74,279,624
JBrowse link
G Gpt glutamic pyruvic transaminase, soluble multiple interactions ISO
EXP
Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in increased activity of GPT protein]
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of GPT protein]
CTD PMID:27743861, PMID:27773935 NCBI chr15:76,696,726...76,699,675
Ensembl chr15:76,695,716...76,699,686
JBrowse link
G Gpx2 glutathione peroxidase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 NCBI chr12:76,792,335...76,795,554
Ensembl chr12:76,792,333...76,795,554
JBrowse link
G Gsta3 glutathione S-transferase, alpha 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA CTD PMID:32152650 NCBI chr 1:21,240,565...21,265,575
Ensembl chr 1:21,240,589...21,265,661
JBrowse link
G Gsta4 glutathione S-transferase, alpha 4 multiple interactions ISO Chenodeoxycholic Acid binds to and results in decreased activity of GSTA4 protein CTD PMID:3954743 NCBI chr 9:78,191,966...78,209,349
Ensembl chr 9:78,182,774...78,209,349
JBrowse link
G Gstk1 glutathione S-transferase kappa 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 6:42,245,935...42,250,441
Ensembl chr 6:42,245,935...42,250,447
JBrowse link
G Gstm1 glutathione S-transferase, mu 1 multiple interactions ISO Chenodeoxycholic Acid binds to and results in decreased activity of GSTM1 protein
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA
CTD PMID:3954743, PMID:32152650 NCBI chr 3:108,012,250...108,017,973
Ensembl chr 3:108,012,255...108,017,973
JBrowse link
G Gstm2 glutathione S-transferase, mu 2 multiple interactions ISO Chenodeoxycholic Acid binds to and results in decreased activity of GSTM2 protein
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA
CTD PMID:3954743, PMID:32152650 NCBI chr 3:107,981,702...107,986,420
Ensembl chr 3:107,981,702...107,986,453
JBrowse link
G Gstm4 glutathione S-transferase, mu 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 3:108,030,571...108,045,179
Ensembl chr 3:108,040,408...108,044,894
JBrowse link
G Herpud1 homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr 8:94,386,429...94,395,371
Ensembl chr 8:94,386,438...94,395,377
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF protein] CTD PMID:15802798 NCBI chr 5:16,553,495...16,619,439
Ensembl chr 5:16,553,495...16,620,152
JBrowse link
G Hhex hematopoietically expressed homeobox multiple interactions
increases expression
ISO
EXP
Chenodeoxycholic Acid promotes the reaction [NR1H4 binds to HHEX intron]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of HHEX mRNA]
NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of HHEX mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of HHEX protein]
Chenodeoxycholic Acid results in increased expression of HHEX mRNA; Chenodeoxycholic Acid results in increased expression of HHEX protein
CTD PMID:19072826 NCBI chr19:37,434,841...37,440,731
Ensembl chr19:37,434,810...37,440,731
JBrowse link
G Hif1a hypoxia inducible factor 1, alpha subunit multiple interactions ISO HIF1A mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA] CTD PMID:24703425 NCBI chr12:73,901,324...73,947,554
Ensembl chr12:73,901,375...73,947,530
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-Coenzyme A reductase decreases response to substance
decreases activity
ISO HMGCR protein results in decreased susceptibility to Chenodeoxycholic Acid
Chenodeoxycholic Acid results in decreased activity of HMGCR protein
CTD PMID:6832710, PMID:7461467 NCBI chr13:96,648,962...96,670,936
Ensembl chr13:96,648,967...96,670,936
JBrowse link
G Hmgcs1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 affects expression ISO Chenodeoxycholic Acid affects the expression of HMGCS1 mRNA CTD PMID:31437187 NCBI chr13:119,690,351...119,708,260
Ensembl chr13:119,690,379...119,708,260
JBrowse link
G Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of HMGCS2 mRNA CTD PMID:27174168 NCBI chr 3:98,280,431...98,310,738
Ensembl chr 3:98,280,435...98,310,738
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA CTD PMID:17724089, PMID:32152650 NCBI chr 8:75,093,618...75,100,593
Ensembl chr 8:75,093,621...75,100,589
JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 decreases activity
increases abundance
multiple interactions
ISO
EXP
Chenodeoxycholic Acid results in decreased activity of HSD11B1 protein
HSD11B1 gene mutant form results in increased abundance of Chenodeoxycholic Acid
[HSD11B1 protein results in increased reduction of 7-ketolithocholic acid] which results in increased chemical synthesis of Chenodeoxycholic Acid
CTD PMID:10664531, PMID:21453287, PMID:25061560 NCBI chr 1:193,221,640...193,264,045
Ensembl chr 1:193,221,634...193,264,075
JBrowse link
G Hspa5 heat shock protein 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA CTD PMID:32152650 NCBI chr 2:34,772,090...34,776,529
Ensembl chr 2:34,771,970...34,777,547
JBrowse link
G Hspb8 heat shock protein 8 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr 5:116,408,491...116,422,864
Ensembl chr 5:116,408,491...116,422,864
JBrowse link
G Icam1 intercellular adhesion molecule 1 increases expression
multiple interactions
EXP
ISO
Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA; Chenodeoxycholic Acid results in increased expression of ICAM1 protein
BAY 11-7085 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA]; SB 203580 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA]
EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 protein]
CTD PMID:16582018, PMID:21224055 NCBI chr 9:21,015,940...21,028,814
Ensembl chr 9:21,015,985...21,028,817
JBrowse link
G Ifng interferon gamma multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide] CTD PMID:12620498 NCBI chr10:118,441,046...118,445,894
Ensembl chr10:118,441,046...118,445,892
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of IGFBP1 mRNA CTD PMID:19072826 NCBI chr11:7,197,787...7,202,546
Ensembl chr11:7,197,782...7,202,546
JBrowse link
G Il10 interleukin 10 decreases abundance EXP IL10 gene mutant form results in decreased abundance of Chenodeoxycholic Acid CTD PMID:27580383 NCBI chr 1:131,019,845...131,024,970
Ensembl chr 1:131,019,845...131,024,974
JBrowse link
G Il1b interleukin 1 beta multiple interactions EXP Chenodeoxycholic Acid affects the reaction [alisol A 24-acetate inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of IL1B mRNA]] CTD PMID:29883724 NCBI chr 2:129,364,569...129,371,164
Ensembl chr 2:129,364,570...129,371,139
JBrowse link
G Jun jun proto-oncogene multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; Chenodeoxycholic Acid results in increased activity of [JUN protein co-treated with FOS protein] CTD PMID:8631127, PMID:32152650 NCBI chr 4:95,049,036...95,052,222
Ensembl chr 4:95,049,034...95,052,222
JBrowse link
G Jund jun D proto-oncogene multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr 8:70,697,739...70,700,616
Ensembl chr 8:70,698,949...70,700,616
JBrowse link
G Lpl lipoprotein lipase multiple interactions EXP Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of LPL mRNA] CTD PMID:27773935 NCBI chr 8:68,880,555...68,906,932
Ensembl chr 8:68,880,491...68,907,448
JBrowse link
G Lrp2 low density lipoprotein receptor-related protein 2 increases expression
multiple interactions
EXP Chenodeoxycholic Acid results in increased expression of LRP2 protein
NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of LRP2 protein]
CTD PMID:15375181 NCBI chr 2:69,424,335...69,586,029
Ensembl chr 2:69,424,340...69,586,065
JBrowse link
G Maf avian musculoaponeurotic fibrosarcoma oncogene homolog multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 NCBI chr 8:115,703,253...115,706,894
Ensembl chr 8:115,682,942...115,707,794
JBrowse link
G Maff v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian) multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 NCBI chr15:79,346,621...79,359,078
Ensembl chr15:79,346,621...79,359,076
JBrowse link
G Mafg v-maf musculoaponeurotic fibrosarcoma oncogene family, protein G (avian) multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr11:120,625,117...120,634,955
Ensembl chr11:120,625,117...120,633,600
JBrowse link
G Mafk v-maf musculoaponeurotic fibrosarcoma oncogene family, protein K (avian) multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr 5:139,791,536...139,802,653
Ensembl chr 5:139,791,513...139,802,653
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression
multiple interactions
EXP
ISO
Chenodeoxycholic Acid results in increased expression of MAP1LC3B protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA
CTD PMID:24189133, PMID:32152650 NCBI chr 8:121,590,438...121,598,760
Ensembl chr 8:121,590,361...121,598,760
JBrowse link
G Map2k1 mitogen-activated protein kinase kinase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr 9:64,185,769...64,253,605
Ensembl chr 9:64,185,770...64,253,631
JBrowse link
G Map2k2 mitogen-activated protein kinase kinase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 NCBI chr10:81,105,913...81,124,697
Ensembl chr10:81,105,915...81,133,975
JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 NCBI chr11:110,399,102...110,525,522
Ensembl chr11:110,399,122...110,525,522
JBrowse link
G Mapk1 mitogen-activated protein kinase 1 increases phosphorylation
multiple interactions
EXP Chenodeoxycholic Acid results in increased phosphorylation of MAPK1 protein
SL 327 inhibits the reaction [Chenodeoxycholic Acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Chenodeoxycholic Acid results in increased phosphorylation of MAPK1 protein]
CTD PMID:19931294 NCBI chr16:16,983,382...17,047,453
Ensembl chr16:16,983,382...17,047,453
JBrowse link
G Mapk3 mitogen-activated protein kinase 3 multiple interactions
increases phosphorylation
EXP SL 327 inhibits the reaction [Chenodeoxycholic Acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Chenodeoxycholic Acid results in increased phosphorylation of MAPK3 protein] CTD PMID:19931294 NCBI chr 7:126,759,626...126,765,816
Ensembl chr 7:126,759,601...126,765,819
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions EXP Chenodeoxycholic Acid inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]; Chenodeoxycholic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK8 protein] CTD PMID:25496033 NCBI chr14:33,377,898...33,447,353
Ensembl chr14:33,377,898...33,447,158
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions EXP
ISO
Chenodeoxycholic Acid inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein]; Chenodeoxycholic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK9 protein]
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA
CTD PMID:25496033, PMID:32152650 NCBI chr11:49,846,728...49,886,421
Ensembl chr11:49,846,751...49,886,421
JBrowse link
G Mapkapk3 mitogen-activated protein kinase-activated protein kinase 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 NCBI chr 9:107,254,927...107,289,877
Ensembl chr 9:107,254,927...107,289,877
JBrowse link
G Mgst2 microsomal glutathione S-transferase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 NCBI chr 3:51,636,912...51,682,675
Ensembl chr 3:51,660,360...51,682,677
JBrowse link
G Mir149 microRNA 149 increases expression ISO Chenodeoxycholic Acid results in increased expression of MIR149 mRNA CTD PMID:27174168 NCBI chr 1:92,850,378...92,850,443
Ensembl chr 1:92,850,378...92,850,443
JBrowse link
G Mir15b microRNA 15b increases expression ISO Chenodeoxycholic Acid results in increased expression of MIR15B mRNA CTD PMID:27174168 NCBI chr 3:69,009,772...69,009,835
Ensembl chr 3:69,009,772...69,009,835
JBrowse link
G Mir190a microRNA 190a decreases expression ISO Chenodeoxycholic Acid results in decreased expression of MIR190A mRNA CTD PMID:27174168 NCBI chr 9:67,236,660...67,236,726
Ensembl chr 9:67,236,660...67,236,726
JBrowse link
G Mir190b microRNA 190b decreases expression ISO Chenodeoxycholic Acid results in decreased expression of MIR190B mRNA CTD PMID:27174168 NCBI chr 3:90,070,020...90,070,099
Ensembl chr 3:90,070,020...90,070,099
JBrowse link
G Mir204 microRNA 204 increases expression ISO Chenodeoxycholic Acid results in increased expression of MIR204 mRNA CTD PMID:27174168 NCBI chr19:22,750,605...22,750,672
Ensembl chr19:22,750,605...22,750,672
JBrowse link
G Mir30a microRNA 30a decreases expression ISO Chenodeoxycholic Acid results in decreased expression of MIR30A mRNA CTD PMID:27174168 NCBI chr 1:23,272,269...23,272,339
Ensembl chr 1:23,272,269...23,272,339
JBrowse link
G Mir3107 microRNA 3107 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of MIR486-2 mRNA CTD PMID:27174168 NCBI chr 8:23,142,573...23,142,662
Ensembl chr 8:23,142,573...23,142,662
JBrowse link
G Mir328 microRNA 328 increases expression ISO Chenodeoxycholic Acid results in increased expression of MIR328 mRNA CTD PMID:27174168 NCBI chr 8:105,308,364...105,308,460
Ensembl chr 8:105,308,364...105,308,460
JBrowse link
G Mir34a microRNA 34a decreases expression ISO Chenodeoxycholic Acid results in decreased expression of MIR34A mRNA CTD PMID:27174168 NCBI chr 4:150,068,454...150,068,555
Ensembl chr 4:150,068,454...150,068,555
JBrowse link
G Mir451a microRNA 451a decreases expression ISO Chenodeoxycholic Acid results in decreased expression of MIR451A mRNA CTD PMID:27174168 NCBI chr11:78,073,170...78,073,241
Ensembl chr11:78,073,170...78,073,241
JBrowse link
G Mir451b microRNA 451b decreases expression ISO Chenodeoxycholic Acid results in decreased expression of MIR451B mRNA CTD PMID:27174168 NCBI chr11:78,073,170...78,073,241
Ensembl chr11:78,073,170...78,073,241
JBrowse link
G Mir452 microRNA 452 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of MIR452 mRNA CTD PMID:27174168 NCBI chr  X:72,262,224...72,262,308
Ensembl chr  X:72,262,224...72,262,308
JBrowse link
G Mir486 microRNA 486 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of MIR486-1 mRNA CTD PMID:27174168 NCBI chr 8:23,142,555...23,142,682
Ensembl chr 8:23,142,555...23,142,682
JBrowse link
G Mir505 microRNA 505 increases expression ISO Chenodeoxycholic Acid results in increased expression of MIR505 mRNA CTD PMID:27174168 NCBI chr  X:60,394,403...60,394,492
Ensembl chr  X:60,394,403...60,394,492
JBrowse link
G Mir92-2 microRNA 92-2 increases expression ISO Chenodeoxycholic Acid results in increased expression of MIR92A2 mRNA CTD PMID:27174168 NCBI chr  X:52,741,838...52,741,928
Ensembl chr  X:52,741,838...52,741,928
JBrowse link
G Mir98 microRNA 98 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of MIR98 mRNA CTD PMID:27174168 NCBI chr  X:151,913,214...151,913,321
Ensembl chr  X:151,913,214...151,913,321
JBrowse link
G Mlkl mixed lineage kinase domain-like multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 NCBI chr 8:111,311,255...111,338,479
Ensembl chr 8:111,311,797...111,338,177
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions EXP Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of MMP2 mRNA] CTD PMID:27773935 NCBI chr 8:92,827,290...92,853,421
Ensembl chr 8:92,827,291...92,853,420
JBrowse link
G Ncoa1 nuclear receptor coactivator 1 multiple interactions ISO Chenodeoxycholic Acid analog promotes the reaction [NR1H4 protein binds to NCOA1 protein]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to NCOA1 protein]; Ketoconazole inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to NCOA1 protein]] CTD PMID:13130122, PMID:14684751, PMID:16819505 NCBI chr12:4,247,362...4,477,206
Ensembl chr12:4,247,362...4,477,182
JBrowse link
G Ncoa2 nuclear receptor coactivator 2 multiple interactions ISO 22,23-dihydroavermectin B(1)a inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; benidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]; cilnidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; clevidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Colchicine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Daunorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; doramectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Doxorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Doxorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; emamectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Epirubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; eprinomectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Felodipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Isradipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Ivermectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; lacidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; moxidectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Nicardipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Nimodipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; pregna-4,17-diene-3,16-dione inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; selamectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]] CTD PMID:25257666, PMID:27773686 NCBI chr 1:13,139,105...13,374,227
Ensembl chr 1:13,139,105...13,374,083
JBrowse link
G Ncor1 nuclear receptor co-repressor 1 multiple interactions ISO 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [NCOR1 protein binds to SLC51A promoter]]; Chenodeoxycholic Acid inhibits the reaction [NCOR1 protein binds to SLC51A promoter] CTD PMID:22291955 NCBI chr11:62,315,663...62,457,414
Ensembl chr11:62,316,426...62,458,541
JBrowse link
G Nfe2l2 nuclear factor, erythroid derived 2, like 2 multiple interactions
increases expression
decreases response to substance
ISO
EXP
[Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of FTL mRNA; [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 mRNA; [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of TXN mRNA; Chenodeoxycholic Acid results in increased expression of and results in increased localization of and results in increased activity of NFE2L2 protein
Chenodeoxycholic Acid results in increased expression of NFE2L2 mRNA
NFE2L2 protein results in decreased susceptibility to Chenodeoxycholic Acid
CTD PMID:17724089, PMID:25582706 NCBI chr 2:75,675,513...75,704,663
Ensembl chr 2:75,675,513...75,704,641
JBrowse link
G Nqo1 NAD(P)H dehydrogenase, quinone 1 multiple interactions
increases expression
ISO
EXP
[Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA
Chenodeoxycholic Acid results in increased expression of NQO1 mRNA
CTD PMID:17724089, PMID:25582706, PMID:32152650 NCBI chr 8:107,388,225...107,403,205
Ensembl chr 8:107,388,225...107,403,206
JBrowse link
G Nqo2 N-ribosyldihydronicotinamide quinone reductase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr13:33,964,655...33,988,465
Ensembl chr13:33,964,687...33,988,443
JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 multiple interactions
increases expression
ISO
EXP
7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]
NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]
[Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of NR0B2 mRNA
CTD PMID:15980055, PMID:16037943, PMID:16269825, PMID:16357303, PMID:16946559, PMID:17963371, PMID:19072826, PMID:19562681, PMID:22178739, PMID:22291955, PMID:22540009, PMID:24189133, PMID:25055961, PMID:25582706, PMID:27174168, PMID:27743861, PMID:29222744 NCBI chr 4:133,553,376...133,556,686
Ensembl chr 4:133,553,376...133,556,536
JBrowse link
G Nr1d1 nuclear receptor subfamily 1, group D, member 1 affects expression ISO Chenodeoxycholic Acid affects the expression of NR1D1 mRNA CTD PMID:31437187 NCBI chr11:98,767,932...98,775,377
Ensembl chr11:98,767,932...98,775,333
JBrowse link
G Nr1d2 nuclear receptor subfamily 1, group D, member 2 increases expression
affects expression
EXP
ISO
Chenodeoxycholic Acid results in increased expression of NR1D2 mRNA
Chenodeoxycholic Acid affects the expression of NR1D2 mRNA
CTD PMID:19072826, PMID:31437187 NCBI chr14:18,204,056...18,239,106
Ensembl chr14:18,204,054...18,239,127
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions
increases expression
increases activity
affects binding
affects activity
increases response to substance
EXP
ISO
Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein; epiallopregnanolone sulfate inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of FOXM1 mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in decreased expression of CYP7A1 mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of HHEX mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of HHEX protein]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in decreased expression of CYP17A1 mRNA]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in decreased expression of SULT2A1 mRNA]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of LRP2 protein]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]; Pregnanolone metabolite inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]
chenodeoxycholic acid enhances the reaction [glycyrrhetinic acid increases expression of Nr1h4 mRNA in liver]
chenodeoxycholic acid increases expression of Nr1H4 mRNA in rat hepatic stellate cells
chenodeoxycholic acid inhibits the reaction [Carbon Tetrachloride decreases expression of Nr1h4 mRNA in rat liver], increases expression of Nr1H4 mRNA in rat liver
Chenodeoxycholic Acid metabolite results in increased activity of NR1H4 protein; Chenodeoxycholic Acid results in increased activity of NR1H4 protein
Chenodeoxycholic Acid results in increased expression of NR1H4 mRNA; Chenodeoxycholic Acid results in increased expression of NR1H4 protein
[Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of NR0B2 mRNA; [Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of SLC51A mRNA; [Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of SLC51B mRNA; Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 mRNA]; Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 mRNA]]
1,4-dihydropyridine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; 22,23-dihydroavermectin B(1)a inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; 22,23-dihydroavermectin B(1)a inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; 4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; 7-hydroxytheonellasterol inhibits the reaction [[Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]] which results in decreased expression of ABCC4 mRNA]; 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]]; 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid results in increased expression of NR1H4 mRNA]; [[Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which binds to ABCB4 promoter] which results in increased expression of ABCB4 mRNA; [[Chenodeoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Chenodeoxycholic Acid analog binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FABP6 mRNA; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]] which results in decreased expression of ABCC4 mRNA; [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to UGT1A3 promoter]] which results in increased expression of UGT1A3 mRNA; [Chenodeoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; abamectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; alpha-Linolenic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Am 580 inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Aminacrine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Arachidonic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; benazepril inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; benidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Chenodeoxycholic Acid analog binds to and results in increased activity of NR1H4 protein; Chenodeoxycholic Acid analog promotes the reaction [NR1H4 protein binds to NCOA1 protein]; Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein; Chenodeoxycholic Acid inhibits the reaction [Ursodeoxycholic Acid binds to NR1H4 protein]; Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]; Chenodeoxycholic Acid promotes the reaction [NR1H4 binds to HHEX intron]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to NCOA1 protein]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to UGT1A3 promoter]; cilnidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; cilnidipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; clevidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Colchicine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; cyclopamine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Daunorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Daunorubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Decitabine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Deoxycholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Docosahexaenoic Acids inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; doramectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; doramectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Doxorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Doxorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Doxorubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; emamectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; emamectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of NR1H4 mRNA]; Epirubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Epirubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; eprinomectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Ethacridine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Felodipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Felodipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; fluoxastrobin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; GW 4064 inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Isotretinoin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Isradipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Ivermectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Ketoconazole inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; lacidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; lacidipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Lithocholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; manidipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Mitomycin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; moxidectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; moxidectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Nicardipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Nicardipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Nimodipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Nitrendipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of HHEX mRNA]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA]; NR1H4 protein affects the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; NR1H4 protein affects the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA]; picoxystrobin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; pirarubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; pregna-4,17-diene-3,16-dione inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Proflavine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Rotenone inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; selamectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; selamectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; ST 1481 inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; tamibarotene inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Topotecan inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Tretinoin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; trifloxystrobin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; UGT1A3 protein affects the reaction [Chenodeoxycholic Acid affects the activity of NR1H4 protein]; Ursodeoxycholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]
NR1H4 results in increased susceptibility to Chenodeoxycholic Acid
CTD PMID:12519787, PMID:12525500, PMID:13130122, PMID:14527955, PMID:14684751, PMID:15145977, PMID:15307955, PMID:15375181, PMID:15489543, PMID:15576845, PMID:15935148, PMID:15980055, PMID:16037943, PMID:16357303, PMID:16423920, PMID:16819505, PMID:16946559, PMID:17058234, PMID:17567710, PMID:17963371, PMID:18180267, PMID:19072826, PMID:19445040, PMID:19562681, PMID:20189675, PMID:21291553, PMID:22135065, PMID:22178739, PMID:22291955, PMID:22414727, PMID:22561792, PMID:22961653, PMID:24703425, PMID:25055961, PMID:25257666, PMID:27743861, PMID:27773686, PMID:27871908, PMID:30408883, PMID:30818834, PMID:32152650, PMID:30061734, PMID:15980055, PMID:19418582 RGD:15092071, RGD:1625201, RGD:15042868 NCBI chr10:89,454,234...89,533,645
Ensembl chr10:89,454,234...89,533,585
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions
increases activity
ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; Chenodeoxycholic Acid analog binds to and results in increased activity of NR1I2 protein; Chenodeoxycholic Acid binds to and results in increased activity of NR1I2 protein
Chenodeoxycholic Acid metabolite results in increased activity of NR1I2 protein
CTD PMID:17963371, PMID:27871908, PMID:32152650 NCBI chr16:38,248,349...38,294,849
Ensembl chr16:38,248,323...38,294,824
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases expression
multiple interactions
decreases expression
EXP
ISO
Chenodeoxycholic Acid results in increased expression of NR1I3 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA
Chenodeoxycholic Acid results in decreased expression of NR1I3 mRNA
CTD PMID:16929008, PMID:27174168, PMID:32152650 NCBI chr 1:171,213,934...171,218,845
Ensembl chr 1:171,213,970...171,220,701
JBrowse link
G Parp1 poly (ADP-ribose) polymerase family, member 1 multiple interactions
increases cleavage
ISO [Chenodeoxycholic Acid co-treated with tauroursodeoxycholic acid] results in increased cleavage of PARP1 protein
Chenodeoxycholic Acid results in increased cleavage of PARP1 protein
CTD PMID:14976352 NCBI chr 1:180,568,891...180,600,999
Ensembl chr 1:180,568,924...180,601,254
JBrowse link
G Pex3 peroxisomal biogenesis factor 3 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of PEX3 mRNA CTD PMID:27174168 NCBI chr10:13,523,842...13,553,142
Ensembl chr10:13,523,842...13,553,142
JBrowse link
G Pik3c2b phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr 1:133,045,672...133,108,691
Ensembl chr 1:133,045,667...133,108,687
JBrowse link
G Pik3c2g phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 NCBI chr 6:139,614,072...139,969,284
Ensembl chr 6:139,587,221...139,969,284
JBrowse link
G Pik3c3 phosphatidylinositol 3-kinase catalytic subunit type 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:30,265,615...30,348,126
Ensembl chr18:30,272,747...30,348,126
JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr13:101,680,761...101,768,217
Ensembl chr13:101,680,563...101,768,217
JBrowse link
G Plaur plasminogen activator, urokinase receptor increases expression EXP Chenodeoxycholic Acid results in increased expression of PLAUR mRNA CTD PMID:21224055 NCBI chr 7:24,460,937...24,475,970
Ensembl chr 7:24,462,484...24,475,968
JBrowse link
G Pon1 paraoxonase 1 multiple interactions
decreases expression
ISO pyrazolanthrone inhibits the reaction [Chenodeoxycholic Acid results in decreased expression of PON1 mRNA] CTD PMID:16269825 NCBI chr 6:5,168,090...5,193,987
Ensembl chr 6:5,168,090...5,193,946
JBrowse link
G Por P450 (cytochrome) oxidoreductase increases abundance EXP POR gene mutant form results in increased abundance of Chenodeoxycholic Acid CTD PMID:25034404 NCBI chr 5:135,670,040...135,735,326
Ensembl chr 5:135,670,033...135,735,326
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha increases expression
multiple interactions
ISO
EXP
Chenodeoxycholic Acid results in increased expression of PPARA mRNA
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of PPARA mRNA]
CTD PMID:15980055, PMID:27773935 NCBI chr15:85,734,910...85,806,851
Ensembl chr15:85,734,983...85,802,819
JBrowse link
G Pparg peroxisome proliferator activated receptor gamma increases expression ISO Chenodeoxycholic Acid results in increased expression of PPARG mRNA CTD PMID:15980055, PMID:27174168 NCBI chr 6:115,360,879...115,490,404
Ensembl chr 6:115,360,951...115,490,399
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
EXP
ISO
Chenodeoxycholic Acid results in increased expression of PTGS2 mRNA
[SLCO1B3 protein results in increased transport of Chenodeoxycholic Acid] which results in increased expression of PTGS2 mRNA
CTD PMID:18648741, PMID:21224055 NCBI chr 1:150,100,031...150,108,234
Ensembl chr 1:150,100,031...150,108,227
JBrowse link
G Rab7 RAB7, member RAS oncogene family decreases expression EXP Chenodeoxycholic Acid results in decreased expression of RAB7 protein CTD PMID:24189133 NCBI chr 6:87,999,106...88,045,270
Ensembl chr 6:87,999,106...88,045,270
JBrowse link
G Rala v-ral simian leukemia viral oncogene A (ras related) multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr13:17,880,575...17,944,217
Ensembl chr13:17,880,571...17,944,239
JBrowse link
G Rap1a RAS-related protein 1a multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 3:105,727,260...105,801,394
Ensembl chr 3:105,727,267...105,801,336
JBrowse link
G Ripk1 receptor (TNFRSF)-interacting serine-threonine kinase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr13:34,002,225...34,035,170
Ensembl chr13:34,002,363...34,037,147
JBrowse link
G Rora RAR-related orphan receptor alpha affects expression ISO Chenodeoxycholic Acid affects the expression of RORA mRNA CTD PMID:31437187 NCBI chr 9:68,653,404...69,388,246
Ensembl chr 9:68,653,786...69,388,246
JBrowse link
G Rras2 related RAS viral (r-ras) oncogene 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr 7:114,046,782...114,117,781
Ensembl chr 7:114,046,782...114,117,781
JBrowse link
G Scarb1 scavenger receptor class B, member 1 increases expression
multiple interactions
ISO Chenodeoxycholic Acid results in increased expression of SCARB1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA
CTD PMID:22540009, PMID:32152650 NCBI chr 5:125,277,087...125,341,094
Ensembl chr 5:125,277,087...125,341,094
JBrowse link
G Scd1 stearoyl-Coenzyme A desaturase 1 multiple interactions EXP Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of SCD1 protein] CTD PMID:27773935 NCBI chr19:44,394,450...44,407,709
Ensembl chr19:44,394,455...44,407,879
JBrowse link
G Sele selectin, endothelial cell multiple interactions
increases expression
ISO BAY 11-7085 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SELE mRNA]; SB 203580 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SELE mRNA] CTD PMID:16582018 NCBI chr 1:164,039,614...164,058,487
Ensembl chr 1:164,048,234...164,057,677
JBrowse link
G Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 multiple interactions
increases expression
EXP
ISO
EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of SERPINE1 mRNA]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA
CTD PMID:21224055, PMID:32152650 NCBI chr 5:137,061,504...137,072,272
Ensembl chr 5:137,061,504...137,072,268
JBrowse link
G Sh3glb1 SH3-domain GRB2-like B1 (endophilin) multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 3:144,683,665...144,720,408
Ensembl chr 3:144,683,678...144,720,335
JBrowse link
G Slc10a1 solute carrier family 10 (sodium/bile acid cotransporter family), member 1 decreases expression
multiple interactions
ISO Chenodeoxycholic Acid results in decreased expression of SLC10A1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA
[Chenodeoxycholic Acid co-treated with Ketoconazole] results in decreased expression of SLC10A1 mRNA; Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLC10A1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLC10A1 mRNA]]
CTD PMID:25055961, PMID:27743861, PMID:30985903, PMID:32152650 NCBI chr12:80,953,185...80,968,705
Ensembl chr12:80,953,183...80,968,705
JBrowse link
G Slc10a2 solute carrier family 10, member 2 multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [SLC10A2 protein results in increased transport of Taurocholic Acid] CTD PMID:25466967 NCBI chr 8:5,083,219...5,105,287
Ensembl chr 8:5,083,219...5,105,351
JBrowse link
G Slc22a1 solute carrier family 22 (organic cation transporter), member 1 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of SLC22A1 mRNA CTD PMID:27174168 NCBI chr17:12,648,874...12,675,838
Ensembl chr17:12,648,869...12,675,829
JBrowse link
G Slc22a7 solute carrier family 22 (organic anion transporter), member 7 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of SLC22A7 mRNA CTD PMID:27174168 NCBI chr17:46,432,185...46,438,477
Ensembl chr17:46,432,183...46,438,457
JBrowse link
G Slc27a5 solute carrier family 27 (fatty acid transporter), member 5 multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [SLC27A5 protein results in increased uptake of Fatty Acids] CTD PMID:22531947 NCBI chr 7:12,988,346...12,998,192
Ensembl chr 7:12,988,346...12,998,192
JBrowse link
G Slc51a solute carrier family 51, alpha subunit multiple interactions
increases expression
ISO
EXP
7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [NCOR1 protein binds to SLC51A promoter]]; 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Calcitriol co-treated with Chenodeoxycholic Acid] results in decreased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; Chenodeoxycholic Acid inhibits the reaction [NCOR1 protein binds to SLC51A promoter]; Chenodeoxycholic Acid promotes the reaction [Oxygen deficiency results in increased expression of SLC51A mRNA]; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; HIF1A mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; NR1H4 protein affects the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; Oxygen deficiency promotes the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]
Chenodeoxycholic Acid results in increased expression of SLC51A mRNA; Chenodeoxycholic Acid results in increased expression of SLC51A protein
[Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of SLC51A mRNA
CTD PMID:16423920, PMID:19562681, PMID:22178739, PMID:22291955, PMID:24703425, PMID:25055961, PMID:25582706, PMID:27174168, PMID:32152650, PMID:32294204 NCBI chr16:32,475,578...32,487,879
Ensembl chr16:32,474,504...32,487,879
JBrowse link
G Slc51b solute carrier family 51, beta subunit multiple interactions
increases expression
ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Calcitriol co-treated with Chenodeoxycholic Acid] results in decreased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA]; NR1H4 protein affects the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA]
Chenodeoxycholic Acid results in increased expression of SLC51B mRNA; Chenodeoxycholic Acid results in increased expression of SLC51B protein
[Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of SLC51B mRNA
CTD PMID:16423920, PMID:19562681, PMID:22178739, PMID:24703425, PMID:25055961, PMID:27174168, PMID:32152650, PMID:32294204 NCBI chr 9:65,412,753...65,422,773
Ensembl chr 9:65,412,714...65,422,955
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 multiple interactions
decreases expression
ISO Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLCO1A2 mRNA]
Chenodeoxycholic Acid results in decreased expression of SLCO1A2 mRNA
CTD PMID:27743861 NCBI chr 6:141,805,438...141,856,284
Ensembl chr 6:141,805,440...141,856,199
JBrowse link
G Slco1b2 solute carrier organic anion transporter family, member 1b2 increases transport
increases expression
multiple interactions
ISO
EXP
SLCO1B3 protein results in increased transport of Chenodeoxycholic Acid
Chenodeoxycholic Acid results in increased expression of SLCO1B2 mRNA
Chenodeoxycholic Acid results in increased expression of SLCO1B3 mRNA
[SLCO1B3 protein results in increased transport of Chenodeoxycholic Acid] which results in increased expression of PTGS2 mRNA
CTD PMID:18648741, PMID:25055961, PMID:25582706, PMID:27174168 NCBI chr 6:141,629,452...141,686,646
Ensembl chr 6:141,629,518...141,686,646
JBrowse link
G Sod2 superoxide dismutase 2, mitochondrial multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA CTD PMID:32152650 NCBI chr17:13,007,839...13,018,119
Ensembl chr17:13,006,846...13,040,063
JBrowse link
G Sqstm1 sequestosome 1 increases expression
multiple interactions
EXP
ISO
Chenodeoxycholic Acid results in increased expression of SQSTM1 protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA
CTD PMID:24189133, PMID:32152650 NCBI chr11:50,200,152...50,210,820
Ensembl chr11:50,199,366...50,210,827
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 decreases expression
multiple interactions
ISO
EXP
Chenodeoxycholic Acid results in decreased expression of SREBF1 mRNA
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of SREBF1 protein]
CTD PMID:16269825, PMID:27773935 NCBI chr11:60,199,084...60,224,186
Ensembl chr11:60,199,089...60,222,581
JBrowse link
G Stip1 stress-induced phosphoprotein 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA CTD PMID:32152650 NCBI chr19:7,020,696...7,040,026
Ensembl chr19:7,020,702...7,039,967
JBrowse link
G Sult1b1 sulfotransferase family 1B, member 1 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of SULT1B1 mRNA CTD PMID:27174168 NCBI chr 5:87,513,327...87,538,195
Ensembl chr 5:87,513,339...87,538,195
JBrowse link
G Sult1c2 sulfotransferase family, cytosolic, 1C, member 2 increases expression ISO Chenodeoxycholic Acid results in increased expression of SULT1C2 mRNA CTD PMID:27174168 NCBI chr17:53,829,637...53,845,958
Ensembl chr17:53,829,637...53,846,339
JBrowse link
G Sult1e1 sulfotransferase family 1E, member 1 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of SULT1E1 mRNA CTD PMID:27174168 NCBI chr 5:87,575,968...87,591,611
Ensembl chr 5:87,575,969...87,591,594
JBrowse link
G Sult2a1 sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 increases sulfation
multiple interactions
decreases expression
ISO
EXP
SULT2A1 protein results in increased sulfation of Chenodeoxycholic Acid
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA
NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in decreased expression of SULT2A1 mRNA]
Chenodeoxycholic Acid results in decreased expression of SULT2A1 mRNA; Chenodeoxycholic Acid results in decreased expression of SULT2A1 protein
CTD PMID:16946559, PMID:20102295, PMID:32152650 NCBI chr 7:13,796,246...13,837,410
Ensembl chr 7:13,796,246...13,837,409
JBrowse link
G Tef thyrotroph embryonic factor increases expression EXP Chenodeoxycholic Acid results in increased expression of TEF mRNA CTD PMID:19072826 NCBI chr15:81,802,673...81,826,863
Ensembl chr15:81,802,421...81,826,863
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TGFB1 mRNA]; Chenodeoxycholic Acid inhibits the reaction [alisol A 24-acetate inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of TGFB1 mRNA]] CTD PMID:27773935, PMID:29883724 NCBI chr 7:25,687,002...25,705,077
Ensembl chr 7:25,687,002...25,705,077
JBrowse link
G Timp1 tissue inhibitor of metalloproteinase 1 multiple interactions EXP Chenodeoxycholic Acid affects the reaction [alisol A 24-acetate inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of TIMP1 mRNA]]; Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TIMP1 mRNA] CTD PMID:27773935, PMID:29883724 NCBI chr  X:20,870,166...20,874,737
Ensembl chr  X:20,870,166...20,874,735
JBrowse link
G Txn1 thioredoxin 1 multiple interactions
increases expression
ISO [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of TXN mRNA
Chenodeoxycholic Acid results in increased expression of TXN protein
CTD PMID:17724089 NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411
JBrowse link
G Ube2k ubiquitin-conjugating enzyme E2K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA CTD PMID:32152650 NCBI chr 5:65,537,245...65,598,989
Ensembl chr 5:65,537,233...65,598,988
JBrowse link
G Ugt1a1 UDP glucuronosyltransferase 1 family, polypeptide A1 increases expression ISO Chenodeoxycholic Acid results in increased expression of UGT1A1 mRNA CTD PMID:27174168 NCBI chr 1:88,211,959...88,220,002
Ensembl chr 1:88,211,959...88,218,997
JBrowse link
G Ugt1a2 UDP glucuronosyltransferase 1 family, polypeptide A2 multiple interactions
increases expression
increases glucuronidation
ISO [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to UGT1A3 promoter]] which results in increased expression of UGT1A3 mRNA; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to UGT1A3 promoter]; shikonin inhibits the reaction [UGT1A3 protein results in increased glucuronidation of Chenodeoxycholic Acid]; UGT1A3 protein affects the reaction [Chenodeoxycholic Acid affects the activity of NR1H4 protein]
Chenodeoxycholic Acid results in increased expression of UGT1A3 mRNA
CTD PMID:17058234, PMID:20189675, PMID:27174168, PMID:31128210 NCBI chr 1:88,200,611...88,220,002
Ensembl chr 1:88,200,601...88,218,997
JBrowse link
G Ugt1a6b UDP glucuronosyltransferase 1 family, polypeptide A6B decreases expression ISO Chenodeoxycholic Acid results in decreased expression of UGT1A6 mRNA CTD PMID:27174168 NCBI chr 1:88,103,257...88,218,998
Ensembl chr 1:88,103,252...88,219,003
JBrowse link
G Ugt1a9 UDP glucuronosyltransferase 1 family, polypeptide A9 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of UGT1A9 mRNA CTD PMID:27174168 NCBI chr 1:88,070,779...88,220,002
Ensembl chr 1:88,070,800...88,218,997
JBrowse link
G Ugt2a3 UDP glucuronosyltransferase 2 family, polypeptide A3 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of UGT2A3 mRNA CTD PMID:27174168 NCBI chr 5:87,324,972...87,337,195
Ensembl chr 5:87,324,972...87,337,195
JBrowse link
G Ugt2b34 UDP glucuronosyltransferase 2 family, polypeptide B34 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of UGT2B7 mRNA CTD PMID:15821044 NCBI chr 5:86,889,770...86,906,937
Ensembl chr 5:86,889,767...86,906,937
JBrowse link
G Usp14 ubiquitin specific peptidase 14 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA CTD PMID:32152650 NCBI chr18:9,993,615...10,030,149
Ensembl chr18:9,993,066...10,045,119
JBrowse link
G Vcam1 vascular cell adhesion molecule 1 increases expression
multiple interactions
EXP
ISO
Chenodeoxycholic Acid results in increased expression of VCAM1 mRNA
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of VCAM1 mRNA]
BAY 11-7085 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of VCAM1 mRNA]; SB 203580 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of VCAM1 mRNA]
Chenodeoxycholic Acid results in increased expression of VCAM1 mRNA; Chenodeoxycholic Acid results in increased expression of VCAM1 protein
CTD PMID:16582018, PMID:21224055, PMID:27773935 NCBI chr 3:116,110,020...116,129,688
Ensembl chr 3:116,109,949...116,129,688
JBrowse link
G Vcp valosin containing protein multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA CTD PMID:32152650 NCBI chr 4:42,979,964...43,000,507
Ensembl chr 4:42,979,963...43,000,507
JBrowse link
G Vdr vitamin D (1,25-dihydroxyvitamin D3) receptor multiple interactions
increases expression
ISO bisindolylmaleimide I inhibits the reaction [Chenodeoxycholic Acid results in increased expression of VDR mRNA]; Chenodeoxycholic Acid promotes the reaction [Calcitriol results in increased expression of VDR mRNA] CTD PMID:20006981 NCBI chr15:97,854,427...97,908,296
Ensembl chr15:97,854,425...97,910,630
JBrowse link
G Vipr1 vasoactive intestinal peptide receptor 1 increases expression ISO Chenodeoxycholic Acid results in increased expression of VIPR1 mRNA; Chenodeoxycholic Acid results in increased expression of VIPR1 protein CTD PMID:16037943 NCBI chr 9:121,642,716...121,672,954
Ensembl chr 9:121,642,716...121,672,954
JBrowse link
deoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP-binding cassette, sub-family B (MDR/TAP), member 11 multiple interactions
increases expression
decreases expression
EXP
ISO
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of ABCB11 mRNA]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA
Deoxycholic Acid results in increased expression of ABCB11 mRNA
CTD PMID:14684751, PMID:21914718, PMID:25055961, PMID:27743861, PMID:32152650 NCBI chr 2:69,238,282...69,342,616
Ensembl chr 2:69,238,282...69,342,616
JBrowse link
G Abcb1a ATP-binding cassette, sub-family B (MDR/TAP), member 1A increases expression ISO Deoxycholic Acid metabolite results in increased expression of ABCB1 mRNA CTD PMID:27871908 NCBI chr 5:8,567,091...8,748,575
Ensembl chr 5:8,660,077...8,748,575
JBrowse link
G Abcb4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 affects expression
increases expression
multiple interactions
EXP Deoxycholic Acid affects the expression of ABCB4 mRNA
Deoxycholic Acid results in increased expression of ABCB4 mRNA
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid affects the expression of ABCB4 mRNA]
CTD PMID:21914718, PMID:25582706 NCBI chr 5:8,893,614...8,959,226
Ensembl chr 5:8,893,717...8,959,231
JBrowse link
G Abcc1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 multiple interactions ISO Deoxycholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr16:14,361,453...14,474,878
Ensembl chr16:14,361,558...14,475,737
JBrowse link
G Abcc2 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 multiple interactions
affects expression
EXP SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid affects the expression of ABCC2 mRNA] CTD PMID:21914718 NCBI chr19:43,782,308...43,838,332
Ensembl chr19:43,782,192...43,840,740
JBrowse link
G Abcc3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 increases activity
multiple interactions
decreases expression
increases expression
affects expression
ISO
EXP
Deoxycholic Acid results in increased activity of ABCC3 protein
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA
Deoxycholic Acid results in decreased expression of ABCC3 mRNA
Deoxycholic Acid results in increased expression of ABCC3 mRNA
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid affects the expression of ABCC3 mRNA]
CTD PMID:17569508, PMID:21914718, PMID:25055961, PMID:25582706, PMID:32152650 NCBI chr11:94,343,295...94,393,017
Ensembl chr11:94,343,295...94,392,997
JBrowse link
G Abcc4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 multiple interactions ISO [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA CTD PMID:32152650 NCBI chr14:118,482,692...118,707,856
Ensembl chr14:118,482,692...118,706,219
JBrowse link
G Abcg5 ATP binding cassette subfamily G member 5 multiple interactions
increases expression
EXP
ISO
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased expression of ABCG5 mRNA] CTD PMID:21914718, PMID:25055961, PMID:25582706 NCBI chr17:84,658,174...84,683,011
Ensembl chr17:84,658,234...84,683,011
JBrowse link
G Abcg8 ATP binding cassette subfamily G member 8 multiple interactions
increases expression
EXP SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased expression of ABCG8 mRNA] CTD PMID:21914718, PMID:25582706 NCBI chr17:84,676,302...84,700,333
Ensembl chr17:84,676,302...84,700,333
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing decreases expression EXP Deoxycholic Acid results in decreased expression of ADIPOQ mRNA CTD PMID:23911798 NCBI chr16:23,146,536...23,157,968
Ensembl chr16:23,146,536...23,158,028
JBrowse link
G Ahr aryl-hydrocarbon receptor multiple interactions
decreases abundance
increases secretion
EXP AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Deoxycholic Acid]
AHR gene mutant form results in decreased abundance of Deoxycholic Acid
AHR gene mutant form results in increased secretion of Deoxycholic Acid
CTD PMID:29452137, PMID:32679164 NCBI chr12:35,497,979...35,534,989
Ensembl chr12:35,497,974...35,535,038
JBrowse link
G Akr1a1 aldo-keto reductase family 1, member A1 (aldehyde reductase) multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 4:116,636,510...116,651,674
Ensembl chr 4:116,636,510...116,651,680
JBrowse link
G Akr7a5 aldo-keto reductase family 7, member A5 (aflatoxin aldehyde reductase) multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 NCBI chr 4:139,310,720...139,318,786
Ensembl chr 4:139,310,744...139,318,426
JBrowse link
G Aldh1a2 aldehyde dehydrogenase family 1, subfamily A2 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of ALDH1A2 mRNA CTD PMID:16556975 NCBI chr 9:71,215,789...71,296,243
Ensembl chr 9:71,215,789...71,296,243
JBrowse link
G Aox1 aldehyde oxidase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 1:58,029,809...58,106,410
Ensembl chr 1:58,029,931...58,106,413
JBrowse link
G Areg amphiregulin increases secretion ISO Deoxycholic Acid results in increased secretion of AREG protein CTD PMID:16213893 NCBI chr 5:91,139,599...91,148,432
Ensembl chr 5:91,139,599...91,148,432
JBrowse link
G Arnt2 aryl hydrocarbon receptor nuclear translocator 2 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of ARNT2 mRNA CTD PMID:16556975 NCBI chr 7:84,246,274...84,411,741
Ensembl chr 7:84,246,278...84,410,176
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr15:80,255,184...80,257,545
Ensembl chr15:80,255,184...80,257,541
JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr 1:170,704,457...170,868,585
Ensembl chr 1:170,704,674...170,867,771
JBrowse link
G Atg7 autophagy related 7 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 6:114,643,127...114,860,604
Ensembl chr 6:114,643,097...114,860,614
JBrowse link
G Atp6v1f ATPase, H+ transporting, lysosomal V1 subunit F multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of ATP6V1F mRNA CTD PMID:16556975 NCBI chr 6:29,467,783...29,470,509
Ensembl chr 6:29,467,718...29,470,512
JBrowse link
G Bax BCL2-associated X protein increases expression
multiple interactions
ISO Deoxycholic Acid results in increased expression of BAX mRNA; Deoxycholic Acid results in increased expression of BAX protein
[Deoxycholic Acid results in increased expression of CCND1 protein] which affects the localization of BAX protein; TP53 protein affects the reaction [[Deoxycholic Acid results in increased expression of CCND1 protein] which affects the localization of BAX protein]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of BAX mRNA]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of BAX protein]
CTD PMID:9562975, PMID:10510466, PMID:17431217, PMID:17881359, PMID:20137712 NCBI chr 7:45,461,695...45,466,903
Ensembl chr 7:45,461,697...45,466,898
JBrowse link
G Bcl2 B cell leukemia/lymphoma 2 decreases response to substance ISO BCL2 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 1:106,538,176...106,714,290
Ensembl chr 1:106,538,178...106,714,274
JBrowse link
G Bnip3 BCL2/adenovirus E1B interacting protein 3 affects response to substance ISO BNIP3 protein affects the susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 7:138,890,836...138,909,506
Ensembl chr 7:138,890,836...138,909,519
JBrowse link
G Casp3 caspase 3 affects response to substance
increases cleavage
increases activity
multiple interactions
ISO CASP3 protein affects the susceptibility to Deoxycholic Acid
Deoxycholic Acid results in increased cleavage of CASP3 protein
Deoxycholic Acid results in increased activity of CASP3 protein
Aspirin inhibits the reaction [Deoxycholic Acid results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [Deoxycholic Acid results in increased cleavage of CASP3 protein]; Deoxycholic Acid results in increased cleavage of and results in increased activity of CASP3 protein
Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased activity of CASP3 protein]
CTD PMID:12507930, PMID:16573382, PMID:17644113, PMID:19054763, PMID:20137712, PMID:21362092 NCBI chr 8:46,617,291...46,639,698
Ensembl chr 8:46,617,291...46,639,689
JBrowse link
G Casp6 caspase 6 affects response to substance
increases activity
multiple interactions
ISO CASP6 protein affects the susceptibility to Deoxycholic Acid
Deoxycholic Acid results in increased activity of CASP6 protein
Aspirin inhibits the reaction [Deoxycholic Acid results in increased activity of CASP6 protein]
CTD PMID:12507930, PMID:17644113 NCBI chr 3:129,901,415...129,914,112
Ensembl chr 3:129,901,425...129,914,103
JBrowse link
G Casp9 caspase 9 multiple interactions
increases cleavage
increases activity
ISO Aspirin inhibits the reaction [Deoxycholic Acid results in increased activity of CASP9 protein]; cobaltiprotoporphyrin inhibits the reaction [Deoxycholic Acid results in increased cleavage of CASP9 protein]; Deoxycholic Acid results in increased cleavage of and results in increased activity of CASP9 protein CTD PMID:17644113, PMID:19054763, PMID:21362092 NCBI chr 4:141,793,612...141,815,978
Ensembl chr 4:141,793,612...141,815,976
JBrowse link
G Cat catalase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 NCBI chr 2:103,453,904...103,485,153
Ensembl chr 2:103,453,849...103,485,160
JBrowse link
G Cbr1 carbonyl reductase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr16:93,607,837...93,610,349
Ensembl chr16:93,605,853...93,610,505
JBrowse link
G Ccl2 chemokine (C-C motif) ligand 2 increases expression EXP Deoxycholic Acid results in increased expression of CCL2 mRNA CTD PMID:21224055, PMID:23911798 NCBI chr11:82,035,577...82,037,452
Ensembl chr11:82,035,571...82,037,453
JBrowse link
G Ccl20 chemokine (C-C motif) ligand 20 increases expression EXP Deoxycholic Acid results in increased expression of CCL20 mRNA CTD PMID:21224055 NCBI chr 1:83,116,766...83,119,167
Ensembl chr 1:83,116,766...83,119,167
JBrowse link
G Ccl5 chemokine (C-C motif) ligand 5 increases expression EXP Deoxycholic Acid results in increased expression of CCL5 mRNA CTD PMID:21224055 NCBI chr11:83,525,778...83,530,518
Ensembl chr11:83,525,778...83,530,518
JBrowse link
G Ccl7 chemokine (C-C motif) ligand 7 increases expression
multiple interactions
EXP Deoxycholic Acid results in increased expression of CCL7 mRNA
EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CCL7 mRNA]
CTD PMID:21224055 NCBI chr11:82,045,712...82,047,525
Ensembl chr11:82,045,712...82,047,525
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
increases expression
ISO [Deoxycholic Acid results in increased expression of CCND1 protein] which affects the localization of BAX protein; tauroursodeoxycholic acid inhibits the reaction [Deoxycholic Acid results in increased expression of CCND1 protein]; TP53 protein affects the reaction [[Deoxycholic Acid results in increased expression of CCND1 protein] which affects the localization of BAX protein]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of CCND1 protein]
Deoxycholic Acid results in increased expression of CCND1 mRNA; Deoxycholic Acid results in increased expression of CCND1 protein
CTD PMID:17431217 NCBI chr 7:144,929,931...144,939,831
Ensembl chr 7:144,929,931...144,939,925
JBrowse link
G Ccr2 chemokine (C-C motif) receptor 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650 NCBI chr 9:124,101,918...124,109,140
Ensembl chr 9:124,101,950...124,113,557
JBrowse link
G Cdh1 cadherin 1 multiple interactions ISO Deoxycholic Acid results in decreased glycosylation of and results in increased degradation of and results in decreased localization of CDH1 protein; Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in increased degradation of CDH1 protein] CTD PMID:22223758 NCBI chr 8:106,603,350...106,670,247
Ensembl chr 8:106,603,351...106,670,246
JBrowse link
G Cebpb CCAAT/enhancer binding protein (C/EBP), beta increases expression
multiple interactions
ISO Deoxycholic Acid results in increased expression of CEBPB
NRAS affects the reaction [Deoxycholic Acid results in increased expression of CEBPB]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of CEBPB]
CTD PMID:18444174 NCBI chr 2:167,688,915...167,690,432
Ensembl chr 2:167,688,915...167,690,418
JBrowse link
G Ces1d carboxylesterase 1D decreases expression EXP Deoxycholic Acid results in decreased expression of CES1D mRNA CTD PMID:23911798 NCBI chr 8:93,166,072...93,197,804
Ensembl chr 8:93,166,068...93,197,838
JBrowse link
G Crot carnitine O-octanoyltransferase decreases expression ISO Deoxycholic Acid results in decreased expression of CROT mRNA CTD PMID:27089845 NCBI chr 5:8,966,033...8,997,146
Ensembl chr 5:8,966,033...8,997,324
JBrowse link
G Csf1 colony stimulating factor 1 (macrophage) multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 NCBI chr 3:107,741,048...107,760,469
Ensembl chr 3:107,741,048...107,760,469
JBrowse link
G Csf1r colony stimulating factor 1 receptor multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of CSF1R mRNA CTD PMID:16556975 NCBI chr18:61,105,572...61,131,139
Ensembl chr18:61,100,598...61,132,149
JBrowse link
G Csf2 colony stimulating factor 2 (granulocyte-macrophage) multiple interactions
increases expression
EXP EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CSF2 mRNA] CTD PMID:21224055 NCBI chr11:54,247,270...54,249,899
Ensembl chr11:54,247,271...54,249,667
JBrowse link
G Csf3 colony stimulating factor 3 (granulocyte) multiple interactions
increases expression
EXP EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CSF3 mRNA] CTD PMID:21224055 NCBI chr11:98,700,183...98,703,631
Ensembl chr11:98,701,263...98,703,629
JBrowse link
G Cxcl10 chemokine (C-X-C motif) ligand 10 increases expression EXP Deoxycholic Acid results in increased expression of CXCL10 mRNA CTD PMID:21224055 NCBI chr 5:92,346,638...92,348,889
Ensembl chr 5:92,346,638...92,348,889
JBrowse link
G Cxcl11 chemokine (C-X-C motif) ligand 11 increases expression EXP Deoxycholic Acid results in increased expression of CXCL11 mRNA CTD PMID:21224055 NCBI chr 5:92,359,544...92,363,296
Ensembl chr 5:92,359,544...92,365,485
JBrowse link
G Cxcl2 chemokine (C-X-C motif) ligand 2 increases expression
multiple interactions
EXP Deoxycholic Acid results in increased expression of CXCL2 mRNA; Deoxycholic Acid results in increased expression of CXCL2 protein
EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of CXCL2 protein]
CTD PMID:21224055 NCBI chr 5:90,903,899...90,905,938
Ensembl chr 5:90,903,871...90,905,938
JBrowse link
G Cxcl3 chemokine (C-X-C motif) ligand 3 increases expression
multiple interactions
EXP Deoxycholic Acid results in increased expression of CXCL1 mRNA
EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CXCL1 mRNA]
CTD PMID:21224055 NCBI chr 5:90,786,101...90,788,093
Ensembl chr 5:90,786,103...90,789,600
JBrowse link
G Cyld CYLD lysine 63 deubiquitinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr 8:88,696,878...88,751,946
Ensembl chr 8:88,697,028...88,751,945
JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 multiple interactions
decreases expression
EXP
ISO
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of CYP27A1 mRNA] CTD PMID:7832767, PMID:21914718, PMID:25582706 NCBI chr 1:74,713,148...74,737,897
Ensembl chr 1:74,713,574...74,737,892
JBrowse link
G Cyp2a22 cytochrome P450, family 2, subfamily a, polypeptide 22 decreases activity ISO Deoxycholic Acid results in decreased activity of CYP2A1 protein CTD PMID:8889968 NCBI chr 7:26,931,631...26,939,413
Ensembl chr 7:26,931,631...26,939,384
JBrowse link
G Cyp2b10 cytochrome P450, family 2, subfamily b, polypeptide 10 multiple interactions
increases expression
ISO Deoxycholic Acid results in decreased expression of and results in decreased activity of CYP2B1 protein; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of and results in decreased activity of CYP2B1 protein]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA
Deoxycholic Acid metabolite results in increased expression of CYP2B6 mRNA
CTD PMID:10453939, PMID:27871908, PMID:32152650 NCBI chr 7:25,897,658...25,926,624
Ensembl chr 7:25,897,620...25,926,624
JBrowse link
G Cyp2c38 cytochrome P450, family 2, subfamily c, polypeptide 38 decreases expression
multiple interactions
ISO Deoxycholic Acid results in decreased expression of CYP2C6V1 protein
Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of CYP2C6V1 protein]
CTD PMID:10453939 NCBI chr19:39,389,556...39,463,103
Ensembl chr19:39,389,556...39,463,075
JBrowse link
G Cyp2c52-ps cytochrome P450, family 2, subfamily c, polypeptide 52, pseudogene decreases activity
multiple interactions
decreases expression
ISO Deoxycholic Acid results in decreased activity of CYP2C11 protein
Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of CYP2C11 protein]
CTD PMID:8889968, PMID:10453939 NCBI chr19:38,976,662...39,003,627
Ensembl chr19:38,976,647...39,003,289
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO Deoxycholic Acid results in decreased expression of and results in decreased activity of CYP2E1 protein; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of and results in decreased activity of CYP2E1 protein] CTD PMID:10453939 NCBI chr 7:140,763,819...140,774,990
Ensembl chr 7:140,763,739...140,774,987
JBrowse link
G Cyp3a11 cytochrome P450, family 3, subfamily a, polypeptide 11 multiple interactions
decreases activity
affects metabolic processing
increases expression
ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA
Deoxycholic Acid metabolite results in decreased activity of CYP3A4 protein
CYP3A4 protein affects the metabolism of Deoxycholic Acid
Deoxycholic Acid metabolite results in increased expression of CYP3A4 mRNA
CTD PMID:15708356, PMID:27871908, PMID:32152650 NCBI chr 5:145,854,607...145,879,854
Ensembl chr 5:145,854,426...145,879,964
JBrowse link
G Cyp4a12b cytochrome P450, family 4, subfamily a, polypeptide 12B decreases expression
multiple interactions
ISO Deoxycholic Acid results in decreased expression of CYP4A1 protein
Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of CYP4A1 protein]
CTD PMID:10453939 NCBI chr 4:115,411,624...115,439,034
Ensembl chr 4:115,411,624...115,439,034
JBrowse link
G Cyp7a1 cytochrome P450, family 7, subfamily a, polypeptide 1 decreases activity
multiple interactions
decreases expression
ISO
EXP
Deoxycholic Acid results in decreased activity of CYP7A1 protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA
Deoxycholic Acid results in decreased expression of CYP7A1 mRNA
[Deoxycholic Acid results in increased activity of NR1H4 protein] which results in increased expression of CYP7A1 mRNA; SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of CYP7A1 mRNA]
CTD PMID:1175606, PMID:14684751, PMID:20671298, PMID:21914718, PMID:22531947, PMID:25055961, PMID:25582706, PMID:32152650 NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633
JBrowse link
G Cyp7b1 cytochrome P450, family 7, subfamily b, polypeptide 1 multiple interactions
decreases expression
EXP SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of CYP7B1 mRNA] CTD PMID:21914718, PMID:25582706 NCBI chr 3:18,071,944...18,243,890
Ensembl chr 3:18,071,950...18,243,338
JBrowse link
G Cyp8b1 cytochrome P450, family 8, subfamily b, polypeptide 1 multiple interactions
decreases expression
EXP
ISO
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of CYP8B1 mRNA] CTD PMID:21914718, PMID:25055961, PMID:25582706 NCBI chr 9:121,914,356...121,916,305
Ensembl chr 9:121,914,356...121,916,305
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA CTD PMID:32152650 NCBI chr10:127,290,793...127,296,291
Ensembl chr10:127,290,774...127,296,288
Ensembl chr10:127,290,774...127,296,288
JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr 8:83,608,175...83,612,653
Ensembl chr 8:83,608,193...83,612,653
JBrowse link
G Dnajb11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr16:22,857,845...22,879,634
Ensembl chr16:22,857,845...22,879,634
JBrowse link
G Dnajb6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 5:29,735,898...29,786,478
Ensembl chr 5:29,735,688...29,818,134
JBrowse link
G Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 NCBI chr12:44,205,897...44,210,068
Ensembl chr12:44,205,559...44,210,326
JBrowse link
G Dnajc1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr 2:18,205,634...18,394,099
Ensembl chr 2:18,195,654...18,392,830
JBrowse link
G Dnajc10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 NCBI chr 2:80,315,446...80,354,055
Ensembl chr 2:80,315,466...80,354,043
JBrowse link
G Dnajc16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 4:141,761,998...141,790,644
Ensembl chr 4:141,760,189...141,790,931
JBrowse link
G Dnajc18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 NCBI chr18:35,671,103...35,708,418
Ensembl chr18:35,671,103...35,708,414
JBrowse link
G Dnajc19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 3:34,057,280...34,081,354
Ensembl chr 3:34,056,020...34,081,321
JBrowse link
G Dnajc21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr15:10,446,763...10,470,568
Ensembl chr15:10,446,756...10,470,516
JBrowse link
G Dnajc3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr14:118,937,932...118,981,702
Ensembl chr14:118,937,976...118,981,697
JBrowse link
G Dnajc6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 4:101,496,648...101,642,799
Ensembl chr 4:101,496,631...101,642,799
JBrowse link
G Dnajc9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 NCBI chr14:20,384,638...20,388,910
Ensembl chr14:20,384,638...20,388,910
JBrowse link
G Egfr epidermal growth factor receptor increases activity
multiple interactions
decreases response to substance
increases phosphorylation
ISO Deoxycholic Acid results in increased activity of EGFR protein
Deoxycholic Acid results in decreased glycosylation of and results in decreased expression of EGFR protein; Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in decreased expression of EGFR protein]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of EGFR protein]
EGFR protein results in decreased susceptibility to Deoxycholic Acid
CTD PMID:12507930, PMID:14747693, PMID:16213893, PMID:22223758 NCBI chr11:16,752,203...16,913,907
Ensembl chr11:16,752,203...16,918,158
JBrowse link
G Egr1 early growth response 1 multiple interactions
increases expression
EXP EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CCL7 mRNA]; EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CSF2 mRNA]; EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CSF3 mRNA]; EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CXCL1 mRNA]; EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of SERPINE1 mRNA]; EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of CXCL2 protein]; EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of ICAM1 protein]; SL 327 inhibits the reaction [Deoxycholic Acid results in increased expression of EGR1 mRNA]; SL 327 inhibits the reaction [Deoxycholic Acid results in increased expression of EGR1 protein]; U 0126 inhibits the reaction [Deoxycholic Acid results in increased expression of EGR1 mRNA]; U 0126 inhibits the reaction [Deoxycholic Acid results in increased expression of EGR1 protein]
Deoxycholic Acid results in increased expression of EGR1 mRNA; Deoxycholic Acid results in increased expression of EGR1 protein
CTD PMID:19931294, PMID:21224055 NCBI chr18:34,861,207...34,864,956
Ensembl chr18:34,859,823...34,864,984
JBrowse link
G Ehhadh enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase decreases expression ISO Deoxycholic Acid results in decreased expression of EHHADH mRNA CTD PMID:27089845 NCBI chr16:21,761,285...21,787,834
Ensembl chr16:21,761,287...21,787,807
JBrowse link
G Enc1 ectodermal-neural cortex 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr13:97,241,105...97,253,040
Ensembl chr13:97,241,105...97,253,034
JBrowse link
G Ephx1 epoxide hydrolase 1, microsomal multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA CTD PMID:32152650 NCBI chr 1:180,989,556...181,017,569
Ensembl chr 1:180,976,210...181,020,904
JBrowse link
G Fabp6 fatty acid binding protein 6 increases expression ISO
EXP
Deoxycholic Acid results in increased expression of FABP6
Deoxycholic Acid results in increased expression of FABP6 mRNA
CTD PMID:22268002, PMID:25582706 NCBI chr11:43,596,040...43,601,562
Ensembl chr11:43,596,049...43,601,540
JBrowse link
G Fgf15 fibroblast growth factor 15 multiple interactions
increases expression
ISO
EXP
[[Deoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Deoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter
Deoxycholic Acid results in increased expression of FGF15 mRNA
Deoxycholic Acid results in increased expression of FGF19; Deoxycholic Acid results in increased expression of FGF19 mRNA
CTD PMID:22268002, PMID:22561792, PMID:25055961, PMID:25582706 NCBI chr 7:144,896,532...144,900,953
Ensembl chr 7:144,896,531...144,900,953
JBrowse link
G Fkbp5 FK506 binding protein 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr17:28,398,753...28,486,149
Ensembl chr17:28,399,094...28,517,527
JBrowse link
G Fmo1 flavin containing monooxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 NCBI chr 1:162,829,561...162,866,610
Ensembl chr 1:162,829,561...162,866,610
JBrowse link
G Fosl1 fos-like antigen 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr19:5,447,698...5,455,938
Ensembl chr19:5,447,547...5,455,946
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions ISO [Deoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of GCLC mRNA CTD PMID:17724089 NCBI chr 9:77,754,535...77,794,489
Ensembl chr 9:77,754,535...77,794,485
JBrowse link
G Gclm glutamate-cysteine ligase, modifier subunit multiple interactions ISO [Deoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of GCLM mRNA CTD PMID:17724089 NCBI chr 3:122,245,487...122,267,215
Ensembl chr 3:122,245,557...122,270,732
JBrowse link
G Gpbar1 G protein-coupled bile acid receptor 1 multiple interactions
increases expression
affects binding
increases response to substance
EXP
ISO
Deoxycholic Acid binds to and results in increased activity of GPBAR1 protein
Deoxycholic Acid results in increased expression of GPBAR1 mRNA
Deoxycholic Acid binds to GPBAR1 protein
GPBAR1 protein results in increased susceptibility to Deoxycholic Acid
CTD PMID:23041323, PMID:23566200, PMID:25055961 NCBI chr 1:74,278,600...74,279,589
Ensembl chr 1:74,278,550...74,279,624
JBrowse link
G Gpx2 glutathione peroxidase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 NCBI chr12:76,792,335...76,795,554
Ensembl chr12:76,792,333...76,795,554
JBrowse link
G Grk2 G protein-coupled receptor kinase 2 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of GRK2 mRNA CTD PMID:16556975 NCBI chr19:4,285,999...4,306,222
Ensembl chr19:4,286,001...4,306,222
JBrowse link
G Gsta3 glutathione S-transferase, alpha 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA CTD PMID:32152650 NCBI chr 1:21,240,565...21,265,575
Ensembl chr 1:21,240,589...21,265,661
JBrowse link
G Gstk1 glutathione S-transferase kappa 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 6:42,245,935...42,250,441
Ensembl chr 6:42,245,935...42,250,447
JBrowse link
G Gstm1 glutathione S-transferase, mu 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA CTD PMID:32152650 NCBI chr 3:108,012,250...108,017,973
Ensembl chr 3:108,012,255...108,017,973
JBrowse link
G Gstm2 glutathione S-transferase, mu 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA CTD PMID:32152650 NCBI chr 3:107,981,702...107,986,420
Ensembl chr 3:107,981,702...107,986,453
JBrowse link
G Gstm4 glutathione S-transferase, mu 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 3:108,030,571...108,045,179
Ensembl chr 3:108,040,408...108,044,894
JBrowse link
G Gstp1 glutathione S-transferase, pi 1 affects binding
multiple interactions
increases response to substance
ISO Deoxycholic Acid binds to GSTP1 protein
gamma-Glu-S-BzCys-PhGly diethyl ester inhibits the reaction [GSTP1 protein results in increased susceptibility to Deoxycholic Acid]
CTD PMID:15300575 NCBI chr19:4,035,411...4,037,912
Ensembl chr19:4,035,407...4,037,985
JBrowse link
G Herpud1 homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr 8:94,386,429...94,395,371
Ensembl chr 8:94,386,438...94,395,377
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO Deoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF protein] CTD PMID:15802798 NCBI chr 5:16,553,495...16,619,439
Ensembl chr 5:16,553,495...16,620,152
JBrowse link
G Hmox1 heme oxygenase 1 decreases response to substance
multiple interactions
ISO HMOX1 protein results in decreased susceptibility to Deoxycholic Acid
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA
CTD PMID:21362092, PMID:32152650 NCBI chr 8:75,093,618...75,100,593
Ensembl chr 8:75,093,621...75,100,589
JBrowse link
G Hoxa1 homeobox A1 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of HOXA1 mRNA CTD PMID:16556975 NCBI chr 6:52,155,367...52,160,007
Ensembl chr 6:52,155,590...52,158,317
JBrowse link
G Hras Harvey rat sarcoma virus oncogene increases activity ISO Deoxycholic Acid results in increased activity of HRAS protein CTD PMID:18444174 NCBI chr 7:141,189,934...141,194,019
Ensembl chr 7:141,189,105...141,194,005
JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 increases abundance EXP HSD11B1 gene mutant form results in increased abundance of Deoxycholic Acid CTD PMID:25061560 NCBI chr 1:193,221,640...193,264,045
Ensembl chr 1:193,221,634...193,264,075
JBrowse link
G Hspa5 heat shock protein 5 decreases response to substance
multiple interactions
ISO HSPA5 protein results in decreased susceptibility to Deoxycholic Acid
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA
CTD PMID:12507930, PMID:32152650 NCBI chr 2:34,772,090...34,776,529
Ensembl chr 2:34,771,970...34,777,547
JBrowse link
G Hspb8 heat shock protein 8 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr 5:116,408,491...116,422,864
Ensembl chr 5:116,408,491...116,422,864
JBrowse link
G Htra1 HtrA serine peptidase 1 affects response to substance ISO HTRA1 protein affects the susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 7:130,936,203...130,985,658
Ensembl chr 7:130,936,111...130,985,660
JBrowse link
G Icam1 intercellular adhesion molecule 1 increases expression
multiple interactions
EXP
ISO
Deoxycholic Acid results in increased expression of ICAM1 mRNA; Deoxycholic Acid results in increased expression of ICAM1 protein
EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of ICAM1 protein]
CTD PMID:16582018, PMID:21224055 NCBI chr 9:21,015,940...21,028,814
Ensembl chr 9:21,015,985...21,028,817
JBrowse link
G Ifng interferon gamma multiple interactions ISO Deoxycholic Acid inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide] CTD PMID:12620498 NCBI chr10:118,441,046...118,445,894
Ensembl chr10:118,441,046...118,445,892
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 decreases expression ISO Deoxycholic Acid results in decreased expression of IGFBP1 mRNA CTD PMID:27089845 NCBI chr11:7,197,787...7,202,546
Ensembl chr11:7,197,782...7,202,546
JBrowse link
G Il10 interleukin 10 increases expression
decreases abundance
multiple interactions
EXP Deoxycholic Acid results in increased expression of IL10 mRNA
IL10 gene mutant form results in decreased abundance of Deoxycholic Acid
Deoxycholic Acid promotes the reaction [irinotecan results in decreased secretion of IL10 protein]
CTD PMID:23911798, PMID:26706406, PMID:27580383 NCBI chr 1:131,019,845...131,024,970
Ensembl chr 1:131,019,845...131,024,974
JBrowse link
G Il1b interleukin 1 beta increases expression EXP Deoxycholic Acid results in increased expression of IL1B mRNA CTD PMID:23911798 NCBI chr 2:129,364,569...129,371,164
Ensembl chr 2:129,364,570...129,371,139
JBrowse link
G Il6 interleukin 6 increases expression EXP Deoxycholic Acid results in increased expression of IL6 mRNA CTD PMID:23911798 NCBI chr 5:30,013,114...30,019,975
Ensembl chr 5:30,013,114...30,019,981
JBrowse link
G Jun jun proto-oncogene multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA CTD PMID:32152650 NCBI chr 4:95,049,036...95,052,222
Ensembl chr 4:95,049,034...95,052,222
JBrowse link
G Jund jun D proto-oncogene multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr 8:70,697,739...70,700,616
Ensembl chr 8:70,698,949...70,700,616
JBrowse link
G Kcnc1 potassium voltage gated channel, Shaw-related subfamily, member 1 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of KCNC1 mRNA CTD PMID:16556975 NCBI chr 7:46,396,219...46,438,706
Ensembl chr 7:46,396,497...46,438,704
JBrowse link
G Klf4 Kruppel-like factor 4 (gut) increases expression EXP Deoxycholic Acid results in increased expression of KLF4 mRNA CTD PMID:27151938 NCBI chr 4:55,527,137...55,532,475
Ensembl chr 4:55,527,143...55,532,466
JBrowse link
G Lep leptin decreases expression EXP Deoxycholic Acid results in decreased expression of LEP mRNA CTD PMID:23911798 NCBI chr 6:29,060,221...29,073,876
Ensembl chr 6:29,060,220...29,073,877
JBrowse link
G Lipe lipase, hormone sensitive decreases expression EXP Deoxycholic Acid results in decreased expression of LIPE mRNA CTD PMID:23911798 NCBI chr 7:25,379,527...25,398,486
Ensembl chr 7:25,379,527...25,398,710
JBrowse link
G Lmna lamin A increases cleavage
multiple interactions
ISO Deoxycholic Acid results in increased cleavage of LMNA protein
Aspirin inhibits the reaction [Deoxycholic Acid results in increased cleavage of LMNA protein]
CTD PMID:17644113 NCBI chr 3:88,481,148...88,509,932
Ensembl chr 3:88,480,147...88,509,956
JBrowse link
G Lpl lipoprotein lipase multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of LPL mRNA CTD PMID:16556975 NCBI chr 8:68,880,555...68,906,932
Ensembl chr 8:68,880,491...68,907,448
JBrowse link
G Maf avian musculoaponeurotic fibrosarcoma oncogene homolog multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 NCBI chr 8:115,703,253...115,706,894
Ensembl chr 8:115,682,942...115,707,794
JBrowse link
G Maff v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian) multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 NCBI chr15:79,346,621...79,359,078
Ensembl chr15:79,346,621...79,359,076
JBrowse link
G Mafg v-maf musculoaponeurotic fibrosarcoma oncogene family, protein G (avian) multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr11:120,625,117...120,634,955
Ensembl chr11:120,625,117...120,633,600
JBrowse link
G Mafk v-maf musculoaponeurotic fibrosarcoma oncogene family, protein K (avian) multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr 5:139,791,536...139,802,653
Ensembl chr 5:139,791,513...139,802,653
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA CTD PMID:32152650 NCBI chr 8:121,590,438...121,598,760
Ensembl chr 8:121,590,361...121,598,760
JBrowse link
G Map2k1 mitogen-activated protein kinase kinase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr 9:64,185,769...64,253,605
Ensembl chr 9:64,185,770...64,253,631
JBrowse link
G Map2k2 mitogen-activated protein kinase kinase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 NCBI chr10:81,105,913...81,124,697
Ensembl chr10:81,105,915...81,133,975
JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 NCBI chr11:110,399,102...110,525,522
Ensembl chr11:110,399,122...110,525,522
JBrowse link
G Mapk1 mitogen-activated protein kinase 1 multiple interactions
increases phosphorylation
ISO
EXP
Deoxycholic Acid results in increased phosphorylation of and results in increased activity of MAPK1 protein; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of and results in increased activity of MAPK1 protein]
SL 327 inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of MAPK1 protein]
CTD PMID:14747693, PMID:19931294 NCBI chr16:16,983,382...17,047,453
Ensembl chr16:16,983,382...17,047,453
JBrowse link
G Mapk3 mitogen-activated protein kinase 3 multiple interactions
increases phosphorylation
ISO
EXP
Deoxycholic Acid results in increased phosphorylation of and results in increased activity of MAPK3 protein; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of and results in increased activity of MAPK3 protein]
SL 327 inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of MAPK3 protein]
CTD PMID:14747693, PMID:19931294 NCBI chr 7:126,759,626...126,765,816
Ensembl chr 7:126,759,601...126,765,819
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA CTD PMID:32152650 NCBI chr11:49,846,728...49,886,421
Ensembl chr11:49,846,751...49,886,421
JBrowse link
G Mapkapk3 mitogen-activated protein kinase-activated protein kinase 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 NCBI chr 9:107,254,927...107,289,877
Ensembl chr 9:107,254,927...107,289,877
JBrowse link
G Mdh1 malate dehydrogenase 1, NAD (soluble) multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of MDH1 mRNA CTD PMID:16556975 NCBI chr11:21,556,692...21,571,934
Ensembl chr11:21,556,692...21,572,367
JBrowse link
G Mdh2 malate dehydrogenase 2, NAD (mitochondrial) multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of MDH2 mRNA CTD PMID:16556975 NCBI chr 5:135,778,649...135,790,386
Ensembl chr 5:135,778,480...135,790,398
JBrowse link
G Mgst2 microsomal glutathione S-transferase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 NCBI chr 3:51,636,912...51,682,675
Ensembl chr 3:51,660,360...51,682,677
JBrowse link
G Mlkl mixed lineage kinase domain-like multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 NCBI chr 8:111,311,255...111,338,479
Ensembl chr 8:111,311,797...111,338,177
JBrowse link
G Mttp microsomal triglyceride transfer protein decreases expression ISO Deoxycholic Acid results in decreased expression of MTTP mRNA CTD PMID:27089845 NCBI chr 3:138,089,855...138,143,418
Ensembl chr 3:138,089,854...138,144,968
JBrowse link
G Naip2 NLR family, apoptosis inhibitory protein 2 decreases response to substance ISO NAIP protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr13:100,144,063...100,202,122
Ensembl chr13:100,144,063...100,202,092
JBrowse link
G Nanog Nanog homeobox increases expression EXP Deoxycholic Acid results in increased expression of NANOG mRNA CTD PMID:27151938 NCBI chr 6:122,707,489...122,714,633
Ensembl chr 6:122,707,489...122,714,633
JBrowse link
G Ncoa1 nuclear receptor coactivator 1 multiple interactions ISO Deoxycholic Acid metabolite promotes the reaction [NR1I2 protein binds to NCOA1 protein] CTD PMID:27871908 NCBI chr12:4,247,362...4,477,206
Ensembl chr12:4,247,362...4,477,182
JBrowse link
G Nfe2l2 nuclear factor, erythroid derived 2, like 2 multiple interactions
increases expression
ISO
EXP
[Deoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of GCLC mRNA; [Deoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of GCLM mRNA
Deoxycholic Acid results in increased expression of NFE2L2 mRNA
CTD PMID:17724089, PMID:25582706 NCBI chr 2:75,675,513...75,704,663
Ensembl chr 2:75,675,513...75,704,641
JBrowse link
G Nfkb1 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 decreases response to substance ISO NFKB1 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 3:135,584,655...135,691,969
Ensembl chr 3:135,584,655...135,691,547
JBrowse link
G Nfkbia nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha multiple interactions
increases phosphorylation
ISO benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal promotes the reaction [Deoxycholic Acid results in increased phosphorylation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Deoxycholic Acid results in increased phosphorylation of NFKBIA protein]; lactacystin promotes the reaction [Deoxycholic Acid results in increased phosphorylation of NFKBIA protein] CTD PMID:17644113 NCBI chr12:55,489,409...55,492,647
Ensembl chr12:55,489,410...55,492,647
JBrowse link
G Nqo1 NAD(P)H dehydrogenase, quinone 1 increases expression
multiple interactions
EXP
ISO
Deoxycholic Acid results in increased expression of NQO1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA
CTD PMID:25582706, PMID:32152650 NCBI chr 8:107,388,225...107,403,205
Ensembl chr 8:107,388,225...107,403,206
JBrowse link
G Nqo2 N-ribosyldihydronicotinamide quinone reductase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr13:33,964,655...33,988,465
Ensembl chr13:33,964,687...33,988,443
JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 increases expression ISO
EXP
Deoxycholic Acid results in increased expression of NR0B2 mRNA CTD PMID:22540009, PMID:25055961, PMID:25582706, PMID:27743861 NCBI chr 4:133,553,376...133,556,686
Ensembl chr 4:133,553,376...133,556,536
JBrowse link
G Nr1d2 nuclear receptor subfamily 1, group D, member 2 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of NR1D2 mRNA CTD PMID:16556975 NCBI chr14:18,204,056...18,239,106
Ensembl chr14:18,204,054...18,239,127
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 increases activity
multiple interactions
decreases expression
increases expression
ISO
EXP
Deoxycholic Acid results in increased activity of NR1H4 protein
[Cholic Acids co-treated with Deoxycholic Acid] results in decreased expression of NR1H4 mRNA
Deoxycholic Acid results in decreased expression of NR1H4 mRNA
[[Deoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Deoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; Deoxycholic Acid analog binds to and results in increased activity of NR1H4 protein; Deoxycholic Acid binds to and results in increased activity of NR1H4 protein; Deoxycholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]
Deoxycholic Acid results in increased expression of NR1H4 mRNA; Deoxycholic Acid results in increased expression of NR1H4 protein
[Deoxycholic Acid results in increased activity of NR1H4 protein] which results in increased expression of CYP7A1 mRNA
CTD PMID:13130122, PMID:14684751, PMID:17567710, PMID:22531947, PMID:22561792, PMID:25055961, PMID:25257666, PMID:27743861, PMID:27871908, PMID:28391356, PMID:32152650 NCBI chr10:89,454,234...89,533,645
Ensembl chr10:89,454,234...89,533,585
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 increases expression
increases activity
multiple interactions
EXP
ISO
Deoxycholic Acid results in increased expression of NR1I2 mRNA
Deoxycholic Acid results in increased activity of NR1I2 protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; Deoxycholic Acid metabolite binds to and results in increased activity of NR1I2 protein; Deoxycholic Acid metabolite promotes the reaction [NR1I2 protein binds to NCOA1 protein]
CTD PMID:25582706, PMID:27871908, PMID:32152650 NCBI chr16:38,248,349...38,294,849
Ensembl chr16:38,248,323...38,294,824
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases expression
multiple interactions
EXP
ISO
Deoxycholic Acid results in increased expression of NR1I3 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA
CTD PMID:16929008, PMID:32152650 NCBI chr 1:171,213,934...171,218,845
Ensembl chr 1:171,213,970...171,220,701
JBrowse link
G Nras neuroblastoma ras oncogene multiple interactions ISO NRAS affects the reaction [Deoxycholic Acid results in increased expression of CEBPB]; NRAS affects the reaction [Deoxycholic Acid results in increased expression of PTGS2] CTD PMID:18444174 NCBI chr 3:103,058,285...103,067,914
Ensembl chr 3:103,058,285...103,067,914
JBrowse link
G Pak1 p21 (RAC1) activated kinase 1 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of PAK1 mRNA CTD PMID:16556975 NCBI chr 7:97,788,541...97,912,381
Ensembl chr 7:97,788,541...97,912,381
JBrowse link
G Parp1 poly (ADP-ribose) polymerase family, member 1 multiple interactions
increases cleavage
ISO Aspirin inhibits the reaction [Deoxycholic Acid results in increased cleavage of PARP1 protein]; cobaltiprotoporphyrin inhibits the reaction [Deoxycholic Acid results in increased cleavage of PARP1 protein] CTD PMID:17644113, PMID:21362092 NCBI chr 1:180,568,891...180,600,999
Ensembl chr 1:180,568,924...180,601,254
JBrowse link
G Pgap2 post-GPI attachment to proteins 2 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of PGAP2 mRNA CTD PMID:16556975 NCBI chr 7:102,209,933...102,238,564
Ensembl chr 7:102,210,208...102,238,567
JBrowse link
G Pik3c2b phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr 1:133,045,672...133,108,691
Ensembl chr 1:133,045,667...133,108,687
JBrowse link
G Pik3c2g phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 NCBI chr 6:139,614,072...139,969,284
Ensembl chr 6:139,587,221...139,969,284
JBrowse link
G Pik3c3 phosphatidylinositol 3-kinase catalytic subunit type 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:30,265,615...30,348,126
Ensembl chr18:30,272,747...30,348,126
JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr13:101,680,761...101,768,217
Ensembl chr13:101,680,563...101,768,217
JBrowse link
G Pip5k1c phosphatidylinositol-4-phosphate 5-kinase, type 1 gamma decreases response to substance ISO PIP5K1C protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr10:81,292,835...81,319,974
Ensembl chr10:81,292,963...81,319,973
JBrowse link
G Plaur plasminogen activator, urokinase receptor increases expression EXP Deoxycholic Acid results in increased expression of PLAUR mRNA CTD PMID:21224055 NCBI chr 7:24,460,937...24,475,970
Ensembl chr 7:24,462,484...24,475,968
JBrowse link
G Plin1 perilipin 1 decreases expression EXP Deoxycholic Acid results in decreased expression of PLIN1 mRNA CTD PMID:23911798 NCBI chr 7:79,721,164...79,732,904
Ensembl chr 7:79,720,218...79,732,903
JBrowse link
G Pnpla2 patatin-like phospholipase domain containing 2 decreases expression EXP Deoxycholic Acid results in decreased expression of PNPLA2 mRNA CTD PMID:23911798 NCBI chr 7:141,455,188...141,460,743
Ensembl chr 7:141,455,198...141,460,743
JBrowse link
G Por P450 (cytochrome) oxidoreductase decreases abundance EXP POR gene mutant form results in decreased abundance of Deoxycholic Acid CTD PMID:25034404 NCBI chr 5:135,670,040...135,735,326
Ensembl chr 5:135,670,033...135,735,326
JBrowse link
G Pou5f1 POU domain, class 5, transcription factor 1 increases expression EXP Deoxycholic Acid results in increased expression of POU5F1 mRNA CTD PMID:27151938 NCBI chr17:35,506,032...35,510,777
Ensembl chr17:35,506,018...35,510,772
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha decreases abundance EXP PPARA gene mutant form results in decreased abundance of Deoxycholic Acid CTD PMID:29175453 NCBI chr15:85,734,910...85,806,851
Ensembl chr15:85,734,983...85,802,819
JBrowse link
G Pparg peroxisome proliferator activated receptor gamma decreases expression EXP Deoxycholic Acid results in decreased expression of PPARG mRNA CTD PMID:23911798 NCBI chr 6:115,360,879...115,490,404
Ensembl chr 6:115,360,951...115,490,399
JBrowse link
G Prdx2 peroxiredoxin 2 decreases response to substance ISO PRDX2 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 8:84,969,622...84,974,811
Ensembl chr 8:84,969,587...84,974,834
JBrowse link
G Prdx4 peroxiredoxin 4 decreases response to substance ISO PRDX4 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr  X:155,323,918...155,342,272
Ensembl chr  X:155,323,918...155,340,754
JBrowse link
G Prkab1 protein kinase, AMP-activated, beta 1 non-catalytic subunit decreases response to substance ISO PRKAB1 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 5:116,013,586...116,024,503
Ensembl chr 5:116,013,586...116,024,508
JBrowse link
G Prkar1a protein kinase, cAMP dependent regulatory, type I, alpha multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of PRKAR1A mRNA CTD PMID:16556975 NCBI chr11:109,649,023...109,669,663
Ensembl chr11:109,649,405...109,669,656
JBrowse link
G Prkca protein kinase C, alpha multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of PRKCA mRNA CTD PMID:16556975 NCBI chr11:107,933,387...108,343,888
Ensembl chr11:107,933,387...108,343,928
JBrowse link
G Prkcb protein kinase C, beta multiple interactions
increases activity
increases expression
ISO Aspirin inhibits the reaction [Deoxycholic Acid results in increased expression of PRKCB protein]; benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal inhibits the reaction [Deoxycholic Acid results in increased expression of PRKCB protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Deoxycholic Acid results in increased expression of PRKCB protein]; lactacystin inhibits the reaction [Deoxycholic Acid results in increased expression of PRKCB protein]
Deoxycholic Acid results in increased activity of PRKCB protein
CTD PMID:7705931, PMID:17644113 NCBI chr 7:122,289,104...122,634,402
Ensembl chr 7:122,288,751...122,634,402
JBrowse link
G Prkce protein kinase C, epsilon multiple interactions
increases cleavage
ISO Aspirin inhibits the reaction [Deoxycholic Acid results in increased cleavage of PRKCE protein] CTD PMID:17644113 NCBI chr17:86,167,785...86,657,919
Ensembl chr17:86,167,785...86,657,919
JBrowse link
G Prkcz protein kinase C, zeta decreases response to substance ISO PRKCZ protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 4:155,260,118...155,361,428
Ensembl chr 4:155,260,129...155,361,361
JBrowse link
G Ptges prostaglandin E synthase multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of PTGES mRNA CTD PMID:16556975 NCBI chr 2:30,889,471...30,931,020
Ensembl chr 2:30,889,471...30,929,863
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
ISO
EXP
Deoxycholic Acid results in increased expression of PTGS2; Deoxycholic Acid results in increased expression of PTGS2 mRNA
[SLCO1B3 protein results in increased transport of Deoxycholic Acid] which results in increased expression of PTGS2 mRNA; NRAS affects the reaction [Deoxycholic Acid results in increased expression of PTGS2]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of PTGS2]
CTD PMID:18444174, PMID:18648741, PMID:21224055 NCBI chr 1:150,100,031...150,108,234
Ensembl chr 1:150,100,031...150,108,227
JBrowse link
G Ptpn2 protein tyrosine phosphatase, non-receptor type 2 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of PTPN2 mRNA CTD PMID:16556975 NCBI chr18:67,665,501...67,724,632
Ensembl chr18:67,665,511...67,724,595
JBrowse link
G Raf1 v-raf-leukemia viral oncogene 1 multiple interactions ISO Deoxycholic Acid results in increased phosphorylation of and results in increased activity of RAF1 protein; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of and results in increased activity of RAF1 protein] CTD PMID:14747693 NCBI chr 6:115,618,569...115,676,635
Ensembl chr 6:115,618,067...115,676,635
JBrowse link
G Rala v-ral simian leukemia viral oncogene A (ras related) multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr13:17,880,575...17,944,217
Ensembl chr13:17,880,571...17,944,239
JBrowse link
G Rap1a RAS-related protein 1a multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 3:105,727,260...105,801,394
Ensembl chr 3:105,727,267...105,801,336
JBrowse link
G Rara retinoic acid receptor, alpha multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of RARA mRNA CTD PMID:16556975 NCBI chr11:98,927,800...98,974,942
Ensembl chr11:98,927,818...98,974,942
JBrowse link
G Rela v-rel reticuloendotheliosis viral oncogene homolog A (avian) decreases response to substance
increases localization
increases expression
multiple interactions
ISO RELA protein results in decreased susceptibility to Deoxycholic Acid
Deoxycholic Acid results in increased localization of RELA protein
Deoxycholic Acid results in increased expression of RELA protein
benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal inhibits the reaction [Deoxycholic Acid results in increased localization of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Deoxycholic Acid results in increased localization of RELA protein]; lactacystin inhibits the reaction [Deoxycholic Acid results in increased localization of RELA protein]
CTD PMID:12507930, PMID:17644113 NCBI chr19:5,637,442...5,648,134
Ensembl chr19:5,637,483...5,648,130
JBrowse link
G Retn resistin decreases expression EXP Deoxycholic Acid results in decreased expression of RETN mRNA CTD PMID:23911798 NCBI chr 8:3,655,770...3,659,818
Ensembl chr 8:3,655,770...3,660,110
JBrowse link
G Ripk1 receptor (TNFRSF)-interacting serine-threonine kinase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr13:34,002,225...34,035,170
Ensembl chr13:34,002,363...34,037,147
JBrowse link
G Rras2 related RAS viral (r-ras) oncogene 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr 7:114,046,782...114,117,781
Ensembl chr 7:114,046,782...114,117,781
JBrowse link
G Rxrg retinoid X receptor gamma multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of RXRG mRNA CTD PMID:16556975 NCBI chr 1:167,598,362...167,639,623
Ensembl chr 1:167,598,384...167,639,623
JBrowse link
G Scarb1 scavenger receptor class B, member 1 increases expression
multiple interactions
ISO Deoxycholic Acid results in increased expression of SCARB1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA
CTD PMID:22540009, PMID:32152650 NCBI chr 5:125,277,087...125,341,094
Ensembl chr 5:125,277,087...125,341,094
JBrowse link
G Sele selectin, endothelial cell increases expression ISO Deoxycholic Acid results in increased expression of SELE mRNA CTD PMID:16582018 NCBI chr 1:164,039,614...164,058,487
Ensembl chr 1:164,048,234...164,057,677
JBrowse link
G Sema6c sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6C multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of SEMA6C mRNA CTD PMID:16556975 NCBI chr 3:95,160,420...95,174,050
Ensembl chr 3:95,160,457...95,174,024
JBrowse link
G Serpinb5 serine (or cysteine) peptidase inhibitor, clade B, member 5 decreases response to substance ISO SERPINB5 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 1:106,861,175...106,883,348
Ensembl chr 1:106,861,173...106,883,348
JBrowse link
G Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 multiple interactions
increases expression
EXP
ISO
EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of SERPINE1 mRNA]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA
CTD PMID:21224055, PMID:32152650 NCBI chr 5:137,061,504...137,072,272
Ensembl chr 5:137,061,504...137,072,268
JBrowse link
G Sh3glb1 SH3-domain GRB2-like B1 (endophilin) multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 3:144,683,665...144,720,408
Ensembl chr 3:144,683,678...144,720,335
JBrowse link
G Sirpa signal-regulatory protein alpha multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of SIRPA mRNA CTD PMID:16556975 NCBI chr 2:129,591,042...129,632,228
Ensembl chr 2:129,592,835...129,632,228
JBrowse link
G Slc10a1 solute carrier family 10 (sodium/bile acid cotransporter family), member 1 increases expression
multiple interactions
decreases expression
EXP
ISO
Deoxycholic Acid results in increased expression of SLC10A1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA
[Cholic Acids co-treated with Deoxycholic Acid] results in decreased expression of SLC10A1 mRNA
Deoxycholic Acid results in decreased expression of SLC10A1 mRNA
CTD PMID:21914718, PMID:25582706, PMID:28391356, PMID:32152650 NCBI chr12:80,953,185...80,968,705
Ensembl chr12:80,953,183...80,968,705
JBrowse link
G Slc15a2 solute carrier family 15 (H+/peptide transporter), member 2 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of SLC15A2 mRNA CTD PMID:16556975 NCBI chr16:36,750,161...36,785,158
Ensembl chr16:36,750,177...36,784,962
JBrowse link
G Slc22a1 solute carrier family 22 (organic cation transporter), member 1 decreases expression EXP Deoxycholic Acid results in decreased expression of SLC22A1 mRNA CTD PMID:21914718 NCBI chr17:12,648,874...12,675,838
Ensembl chr17:12,648,869...12,675,829
JBrowse link
G Slc22a7 solute carrier family 22 (organic anion transporter), member 7 affects expression
multiple interactions
EXP Deoxycholic Acid affects the expression of SLC22A7 mRNA
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid affects the expression of SLC22A7 mRNA]
CTD PMID:21914718 NCBI chr17:46,432,185...46,438,477
Ensembl chr17:46,432,183...46,438,457
JBrowse link
G Slc22a8 solute carrier family 22 (organic anion transporter), member 8 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of SLC22A8 mRNA CTD PMID:16556975 NCBI chr19:8,591,254...8,611,835
Ensembl chr19:8,591,254...8,611,835
JBrowse link
G Slc27a2 solute carrier family 27 (fatty acid transporter), member 2 multiple interactions ISO Deoxycholic Acid inhibits the reaction [SLC27A2 protein results in increased uptake of Fatty Acids] CTD PMID:22531947 NCBI chr 2:126,553,024...126,588,243
Ensembl chr 2:126,552,407...126,588,243
JBrowse link
G Slc27a5 solute carrier family 27 (fatty acid transporter), member 5 multiple interactions ISO
EXP
Deoxycholic Acid inhibits the reaction [SLC27A5 protein results in increased uptake of Fatty Acids] CTD PMID:22531947 NCBI chr 7:12,988,346...12,998,192
Ensembl chr 7:12,988,346...12,998,192
JBrowse link
G Slc51a solute carrier family 51, alpha subunit decreases expression
multiple interactions
increases expression
EXP
ISO
Deoxycholic Acid results in decreased expression of SLC51A mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA
Deoxycholic Acid results in increased expression of SLC51A mRNA
Deoxycholic Acid results in increased expression of SLC51A; Deoxycholic Acid results in increased expression of SLC51A mRNA
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of SLC51A mRNA]
CTD PMID:21914718, PMID:22268002, PMID:25055961, PMID:25582706, PMID:32152650 NCBI chr16:32,475,578...32,487,879
Ensembl chr16:32,474,504...32,487,879
JBrowse link
G Slc51b solute carrier family 51, beta subunit multiple interactions
increases expression
EXP
ISO
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased expression of SLC51B mRNA]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA
Deoxycholic Acid results in increased expression of SLC51B; Deoxycholic Acid results in increased expression of SLC51B mRNA
CTD PMID:21914718, PMID:22268002, PMID:25055961, PMID:25582706, PMID:32152650 NCBI chr 9:65,412,753...65,422,773
Ensembl chr 9:65,412,714...65,422,955
JBrowse link
G Slco1a1 solute carrier organic anion transporter family, member 1a1 multiple interactions
decreases expression
EXP SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid affects the expression of ABCB4 mRNA]; SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid affects the expression of ABCC2 mRNA]; SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid affects the expression of ABCC3 mRNA]; SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid affects the expression of SLC22A7 mRNA]; SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of ABCB11 mRNA]; SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of CYP27A1 mRNA]; SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of CYP7A1 mRNA]; SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of CYP7B1 mRNA]; SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of CYP8B1 mRNA]; SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of SLC51A mRNA]; SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased abundance of Bile Acids and Salts]; SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased abundance of Glycodeoxycholic Acid]; SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased abundance of Taurodeoxycholic Acid]; SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased expression of ABCG5 mRNA]; SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased expression of ABCG8 mRNA]; SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased expression of SLC51B mRNA]; SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased expression of SLCO1A4 mRNA]; SLCO1A1 protein affects the susceptibility to and affects the abundance of Deoxycholic Acid
Deoxycholic Acid results in decreased expression of SLCO1A1 mRNA
CTD PMID:21914718, PMID:25582706 NCBI chr 6:141,907,281...141,946,962
Ensembl chr 6:141,907,282...141,946,962
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 increases expression
multiple interactions
EXP Deoxycholic Acid results in increased expression of SLCO1A4 mRNA
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased expression of SLCO1A4 mRNA]
CTD PMID:21914718 NCBI chr 6:141,805,438...141,856,284
Ensembl chr 6:141,805,440...141,856,199
JBrowse link
G Slco1b2 solute carrier organic anion transporter family, member 1b2 multiple interactions
affects expression
increases expression
increases uptake
increases transport
ISO
EXP
[SLCO1B3 protein results in increased transport of Deoxycholic Acid] which results in increased expression of PTGS2 mRNA
Deoxycholic Acid affects the expression of SLCO1B2 mRNA
Deoxycholic Acid results in increased expression of SLCO1B3 mRNA
SLCO1B3 protein results in increased uptake of Deoxycholic Acid
CTD PMID:16534140, PMID:18648741, PMID:25055961, PMID:25582706 NCBI chr 6:141,629,452...141,686,646
Ensembl chr 6:141,629,518...141,686,646
JBrowse link
G Sod2 superoxide dismutase 2, mitochondrial multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]; Curcumin analog promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein] CTD PMID:22316666, PMID:32152650 NCBI chr17:13,007,839...13,018,119
Ensembl chr17:13,006,846...13,040,063
JBrowse link
G Sox2 SRY (sex determining region Y)-box 2 increases expression EXP Deoxycholic Acid results in increased expression of SOX2 mRNA CTD PMID:27151938 NCBI chr 3:34,649,995...34,652,461
Ensembl chr 3:34,650,405...34,652,461
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA CTD PMID:32152650 NCBI chr11:50,200,152...50,210,820
Ensembl chr11:50,199,366...50,210,827
JBrowse link
G Sstr3 somatostatin receptor 3 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of SSTR3 mRNA CTD PMID:16556975 NCBI chr15:78,537,014...78,549,365
Ensembl chr15:78,537,008...78,544,685
JBrowse link
G Stip1 stress-induced phosphoprotein 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA CTD PMID:32152650 NCBI chr19:7,020,696...7,040,026
Ensembl chr19:7,020,702...7,039,967
JBrowse link
G Stk11 serine/threonine kinase 11 increases phosphorylation ISO Deoxycholic Acid results in increased phosphorylation of STK11 protein CTD PMID:27743861 NCBI chr10:80,115,767...80,130,679
Ensembl chr10:80,115,803...80,130,682
JBrowse link
G Sult2a1 sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA CTD PMID:32152650 NCBI chr 7:13,796,246...13,837,410
Ensembl chr 7:13,796,246...13,837,409
JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases expression
ISO Deoxycholic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
Deoxycholic Acid results in decreased expression of TNF mRNA
CTD PMID:23566200, PMID:23627780 NCBI chr17:35,199,367...35,202,007
Ensembl chr17:35,199,381...35,202,007
JBrowse link
G Traf2 TNF receptor-associated factor 2 decreases response to substance ISO TRAF2 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 2:25,517,982...25,546,940
Ensembl chr 2:25,517,982...25,546,940
JBrowse link
G Trp53 transformation related protein 53 increases expression
multiple interactions
ISO Deoxycholic Acid results in increased expression of TP53 mRNA
TP53 protein affects the reaction [[Deoxycholic Acid results in increased expression of CCND1 protein] which affects the localization of BAX protein]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of TP53 mRNA]
CTD PMID:17431217, PMID:20137712 NCBI chr11:69,580,348...69,591,873
Ensembl chr11:69,580,359...69,591,873
JBrowse link
G Ube2i ubiquitin-conjugating enzyme E2I multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of UBE2I mRNA CTD PMID:16556975 NCBI chr17:25,260,510...25,275,799
Ensembl chr17:25,261,916...25,274,622
JBrowse link
G Ube2k ubiquitin-conjugating enzyme E2K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA CTD PMID:32152650 NCBI chr 5:65,537,245...65,598,989
Ensembl chr 5:65,537,233...65,598,988
JBrowse link
G Usp14 ubiquitin specific peptidase 14 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA CTD PMID:32152650 NCBI chr18:9,993,615...10,030,149
Ensembl chr18:9,993,066...10,045,119
JBrowse link
G Vamp2 vesicle-associated membrane protein 2 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of VAMP2 mRNA CTD PMID:16556975 NCBI chr11:69,088,528...69,092,381
Ensembl chr11:69,088,490...69,092,384
JBrowse link
G Vax2 ventral anterior homeobox 2 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of VAX2 mRNA CTD PMID:16556975 NCBI chr 6:83,711,239...83,738,313
Ensembl chr 6:83,711,264...83,738,313
JBrowse link
G Vcam1 vascular cell adhesion molecule 1 increases expression EXP
ISO
Deoxycholic Acid results in increased expression of VCAM1 mRNA
Deoxycholic Acid results in increased expression of VCAM1 mRNA; Deoxycholic Acid results in increased expression of VCAM1 protein
CTD PMID:16582018, PMID:21224055 NCBI chr 3:116,110,020...116,129,688
Ensembl chr 3:116,109,949...116,129,688
JBrowse link
G Vcp valosin containing protein multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA CTD PMID:32152650 NCBI chr 4:42,979,964...43,000,507
Ensembl chr 4:42,979,963...43,000,507
JBrowse link
glycochenodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP-binding cassette, sub-family B (MDR/TAP), member 11 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA CTD PMID:32152650 NCBI chr 2:69,238,282...69,342,616
Ensembl chr 2:69,238,282...69,342,616
JBrowse link
G Abcc3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA CTD PMID:32152650 NCBI chr11:94,343,295...94,393,017
Ensembl chr11:94,343,295...94,392,997
JBrowse link
G Abcc4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 multiple interactions ISO [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA CTD PMID:32152650 NCBI chr14:118,482,692...118,707,856
Ensembl chr14:118,482,692...118,706,219
JBrowse link
G Agt angiotensinogen (serpin peptidase inhibitor, clade A, member 8) multiple interactions
decreases response to substance
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased expression of DDIT3 mRNA]; AGTR1 protein promotes the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; AGTR1 protein promotes the reaction [AGT protein results in decreased susceptibility to Glycochenodeoxycholic Acid]; candesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; irbesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Losartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; SB 203580 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; U 0126 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Valsartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]] CTD PMID:23300732 NCBI chr 8:124,556,587...124,569,706
Ensembl chr 8:124,556,534...124,569,706
JBrowse link
G Agtr1a angiotensin II receptor, type 1a multiple interactions ISO AGTR1 protein promotes the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; AGTR1 protein promotes the reaction [AGT protein results in decreased susceptibility to Glycochenodeoxycholic Acid] CTD PMID:23300732 NCBI chr13:30,336,356...30,382,867
Ensembl chr13:30,336,441...30,382,867
JBrowse link
G Akr1a1 aldo-keto reductase family 1, member A1 (aldehyde reductase) multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 4:116,636,510...116,651,674
Ensembl chr 4:116,636,510...116,651,680
JBrowse link
G Akr7a5 aldo-keto reductase family 7, member A5 (aflatoxin aldehyde reductase) multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 NCBI chr 4:139,310,720...139,318,786
Ensembl chr 4:139,310,744...139,318,426
JBrowse link
G Aox1 aldehyde oxidase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 1:58,029,809...58,106,410
Ensembl chr 1:58,029,931...58,106,413
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr15:80,255,184...80,257,545
Ensembl chr15:80,255,184...80,257,541
JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr 1:170,704,457...170,868,585
Ensembl chr 1:170,704,674...170,867,771
JBrowse link
G Atg5 autophagy related 5 decreases expression
multiple interactions
ISO Glycochenodeoxycholic Acid results in decreased expression of ATG5 mRNA; Glycochenodeoxycholic Acid results in decreased expression of ATG5 protein
TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of ATG5 mRNA]
CTD PMID:32439580 NCBI chr10:44,268,322...44,364,299
Ensembl chr10:44,268,358...44,364,291
JBrowse link
G Atg7 autophagy related 7 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 6:114,643,127...114,860,604
Ensembl chr 6:114,643,097...114,860,614
JBrowse link
G Atp6v0d1 ATPase, H+ transporting, lysosomal V0 subunit D1 decreases expression ISO Glycochenodeoxycholic Acid results in decreased expression of ATP6V0D1 mRNA CTD PMID:32439580 NCBI chr 8:105,524,461...105,566,064
Ensembl chr 8:105,524,465...105,566,047
JBrowse link
G Atp6v1e1 ATPase, H+ transporting, lysosomal V1 subunit E1 decreases expression ISO Glycochenodeoxycholic Acid results in decreased expression of ATP6V1E1 mRNA CTD PMID:32439580 NCBI chr 6:120,795,244...120,822,698
Ensembl chr 6:120,794,305...120,822,793
JBrowse link
G Bcl2a1b B cell leukemia/lymphoma 2 related protein A1b increases expression ISO Glycochenodeoxycholic Acid results in increased expression of BCL2A1 mRNA CTD PMID:15767249 NCBI chr 9:89,199,273...89,207,838
Ensembl chr 9:89,199,209...89,207,827
JBrowse link
G Bcl2l13 BCL2-like 13 (apoptosis facilitator) decreases expression ISO Glycochenodeoxycholic Acid results in decreased expression of BCL2L13 protein CTD PMID:32439580 NCBI chr 6:120,836,206...120,892,842
Ensembl chr 6:120,836,212...120,892,842
JBrowse link
G Becn1 beclin 1, autophagy related decreases expression
multiple interactions
ISO Glycochenodeoxycholic Acid results in decreased expression of BECN1 mRNA; Glycochenodeoxycholic Acid results in decreased expression of BECN1 protein
TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of BECN1 mRNA]
CTD PMID:32439580 NCBI chr11:101,288,258...101,302,286
Ensembl chr11:101,285,952...101,302,286
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 increases expression ISO Glycochenodeoxycholic Acid results in increased expression of BIRC5 mRNA CTD PMID:15767249 NCBI chr11:117,849,237...117,855,743
Ensembl chr11:117,849,251...117,855,743
JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
increases activity
ISO
EXP
Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Calcimycin inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Egtazic Acid promotes the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Nitric Oxide inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Sulfasalazine inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]
lysophosphatidylethanolamine analog inhibits the reaction [Glycochenodeoxycholic Acid results in increased cleavage of CASP3 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGTR1 protein promotes the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; candesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; irbesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Losartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; SB 203580 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; U 0126 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Valsartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]
CTD PMID:12873810, PMID:15767249, PMID:16322111, PMID:19837105, PMID:20020783, PMID:23300732, PMID:25125499 NCBI chr 8:46,617,291...46,639,698
Ensembl chr 8:46,617,291...46,639,689
JBrowse link
G Casp8 caspase 8 increases activity
increases cleavage
ISO
EXP
Glycochenodeoxycholic Acid results in increased activity of CASP8 protein
Glycochenodeoxycholic Acid results in increased cleavage of CASP8 protein
CTD PMID:12873810, PMID:15767249, PMID:25125499 NCBI chr 1:58,795,233...58,847,503
Ensembl chr 1:58,795,374...58,847,503
JBrowse link
G Casp9 caspase 9 increases activity
multiple interactions
ISO Glycochenodeoxycholic Acid results in increased activity of CASP9 protein
Sulfasalazine inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP9 protein]
CTD PMID:15767249, PMID:16322111 NCBI chr 4:141,793,612...141,815,978
Ensembl chr 4:141,793,612...141,815,976
JBrowse link
G Cat catalase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 NCBI chr 2:103,453,904...103,485,153
Ensembl chr 2:103,453,849...103,485,160
JBrowse link
G Cbr1 carbonyl reductase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr16:93,607,837...93,610,349
Ensembl chr16:93,605,853...93,610,505
JBrowse link
G Ccr2 chemokine (C-C motif) receptor 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650 NCBI chr 9:124,101,918...124,109,140
Ensembl chr 9:124,101,950...124,113,557
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator multiple interactions
increases expression
ISO
EXP
Glycochenodeoxycholic Acid results in decreased expression of and results in increased phosphorylation of CFLAR protein
Glycochenodeoxycholic Acid results in increased expression of CFLAR protein
Glycochenodeoxycholic Acid promotes the reaction [lysophosphatidylethanolamine analog results in increased expression of CFLAR protein]; lysophosphatidylethanolamine analog promotes the reaction [Glycochenodeoxycholic Acid results in increased expression of CFLAR protein]
CTD PMID:25125499 NCBI chr 1:58,711,311...58,758,884
Ensembl chr 1:58,711,508...58,758,884
JBrowse link
G Csf1 colony stimulating factor 1 (macrophage) multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 NCBI chr 3:107,741,048...107,760,469
Ensembl chr 3:107,741,048...107,760,469
JBrowse link
G Cycs cytochrome c, somatic affects localization ISO Glycochenodeoxycholic Acid affects the localization of CYCS protein CTD PMID:15767249 NCBI chr 6:50,562,563...50,566,569
Ensembl chr 6:50,562,563...50,566,538
JBrowse link
G Cyld CYLD lysine 63 deubiquitinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr 8:88,696,878...88,751,946
Ensembl chr 8:88,697,028...88,751,945
JBrowse link
G Cyp2b10 cytochrome P450, family 2, subfamily b, polypeptide 10 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA CTD PMID:32152650 NCBI chr 7:25,897,658...25,926,624
Ensembl chr 7:25,897,620...25,926,624
JBrowse link
G Cyp3a11 cytochrome P450, family 3, subfamily a, polypeptide 11 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA CTD PMID:32152650 NCBI chr 5:145,854,607...145,879,854
Ensembl chr 5:145,854,426...145,879,964
JBrowse link
G Cyp7a1 cytochrome P450, family 7, subfamily a, polypeptide 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA CTD PMID:32152650 NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions
increases expression
ISO AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased expression of DDIT3 mRNA]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA
CTD PMID:23300732, PMID:32152650 NCBI chr10:127,290,793...127,296,291
Ensembl chr10:127,290,774...127,296,288
Ensembl chr10:127,290,774...127,296,288
JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr 8:83,608,175...83,612,653
Ensembl chr 8:83,608,193...83,612,653
JBrowse link
G Dnajb11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr16:22,857,845...22,879,634
Ensembl chr16:22,857,845...22,879,634
JBrowse link
G Dnajb6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 5:29,735,898...29,786,478
Ensembl chr 5:29,735,688...29,818,134
JBrowse link
G Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 NCBI chr12:44,205,897...44,210,068
Ensembl chr12:44,205,559...44,210,326
JBrowse link
G Dnajc1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr 2:18,205,634...18,394,099
Ensembl chr 2:18,195,654...18,392,830
JBrowse link
G Dnajc10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 NCBI chr 2:80,315,446...80,354,055
Ensembl chr 2:80,315,466...80,354,043
JBrowse link
G Dnajc16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 4:141,761,998...141,790,644
Ensembl chr 4:141,760,189...141,790,931
JBrowse link
G Dnajc18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 NCBI chr18:35,671,103...35,708,418
Ensembl chr18:35,671,103...35,708,414
JBrowse link
G Dnajc19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 3:34,057,280...34,081,354
Ensembl chr 3:34,056,020...34,081,321
JBrowse link
G Dnajc21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr15:10,446,763...10,470,568
Ensembl chr15:10,446,756...10,470,516
JBrowse link
G Dnajc3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr14:118,937,932...118,981,702
Ensembl chr14:118,937,976...118,981,697
JBrowse link
G Dnajc6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 4:101,496,648...101,642,799
Ensembl chr 4:101,496,631...101,642,799
JBrowse link
G Dnajc9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 NCBI chr14:20,384,638...20,388,910
Ensembl chr14:20,384,638...20,388,910
JBrowse link
G Enc1 ectodermal-neural cortex 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr13:97,241,105...97,253,040
Ensembl chr13:97,241,105...97,253,034
JBrowse link
G Ephx1 epoxide hydrolase 1, microsomal multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA CTD PMID:32152650 NCBI chr 1:180,989,556...181,017,569
Ensembl chr 1:180,976,210...181,020,904
JBrowse link
G Fkbp5 FK506 binding protein 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr17:28,398,753...28,486,149
Ensembl chr17:28,399,094...28,517,527
JBrowse link
G Fmo1 flavin containing monooxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 NCBI chr 1:162,829,561...162,866,610
Ensembl chr 1:162,829,561...162,866,610
JBrowse link
G Fosl1 fos-like antigen 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr19:5,447,698...5,455,938
Ensembl chr19:5,447,547...5,455,946
JBrowse link
G Gpx2 glutathione peroxidase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 NCBI chr12:76,792,335...76,795,554
Ensembl chr12:76,792,333...76,795,554
JBrowse link
G Gsta3 glutathione S-transferase, alpha 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA
Glycochenodeoxycholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]
CTD PMID:3783048, PMID:32152650 NCBI chr 1:21,240,565...21,265,575
Ensembl chr 1:21,240,589...21,265,661
JBrowse link
G Gstk1 glutathione S-transferase kappa 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 6:42,245,935...42,250,441
Ensembl chr 6:42,245,935...42,250,447
JBrowse link
G Gstm1 glutathione S-transferase, mu 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA CTD PMID:32152650 NCBI chr 3:108,012,250...108,017,973
Ensembl chr 3:108,012,255...108,017,973
JBrowse link
G Gstm2 glutathione S-transferase, mu 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA CTD PMID:32152650 NCBI chr 3:107,981,702...107,986,420
Ensembl chr 3:107,981,702...107,986,453
JBrowse link
G Gstm4 glutathione S-transferase, mu 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 3:108,030,571...108,045,179
Ensembl chr 3:108,040,408...108,044,894
JBrowse link
G Herpud1 homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr 8:94,386,429...94,395,371
Ensembl chr 8:94,386,438...94,395,377
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO Glycochenodeoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF protein] CTD PMID:15802798 NCBI chr 5:16,553,495...16,619,439
Ensembl chr 5:16,553,495...16,620,152
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA CTD PMID:32152650 NCBI chr 8:75,093,618...75,100,593
Ensembl chr 8:75,093,621...75,100,589
JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 decreases abundance EXP HSD11B1 gene mutant form results in decreased abundance of Glycochenodeoxycholic Acid CTD PMID:25061560 NCBI chr 1:193,221,640...193,264,045
Ensembl chr 1:193,221,634...193,264,075
JBrowse link
G Hspa5 heat shock protein 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA CTD PMID:32152650 NCBI chr 2:34,772,090...34,776,529
Ensembl chr 2:34,771,970...34,777,547
JBrowse link
G Hspb8 heat shock protein 8 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr 5:116,408,491...116,422,864
Ensembl chr 5:116,408,491...116,422,864
JBrowse link
G Huwe1 HECT, UBA and WWE domain containing 1 multiple interactions ISO Glycochenodeoxycholic Acid inhibits the reaction [HUWE1 protein binds to MCL1 protein] CTD PMID:21507240 NCBI chr  X:151,800,785...151,935,417
Ensembl chr  X:151,800,807...151,935,417
JBrowse link
G Jun jun proto-oncogene multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA CTD PMID:32152650 NCBI chr 4:95,049,036...95,052,222
Ensembl chr 4:95,049,034...95,052,222
JBrowse link
G Jund jun D proto-oncogene multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr 8:70,697,739...70,700,616
Ensembl chr 8:70,698,949...70,700,616
JBrowse link
G Maf avian musculoaponeurotic fibrosarcoma oncogene homolog multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 NCBI chr 8:115,703,253...115,706,894
Ensembl chr 8:115,682,942...115,707,794
JBrowse link
G Maff v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian) multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 NCBI chr15:79,346,621...79,359,078
Ensembl chr15:79,346,621...79,359,076
JBrowse link
G Mafg v-maf musculoaponeurotic fibrosarcoma oncogene family, protein G (avian) multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr11:120,625,117...120,634,955
Ensembl chr11:120,625,117...120,633,600
JBrowse link
G Mafk v-maf musculoaponeurotic fibrosarcoma oncogene family, protein K (avian) multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr 5:139,791,536...139,802,653
Ensembl chr 5:139,791,513...139,802,653
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions
decreases expression
ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of MAP1LC3B mRNA] CTD PMID:32152650, PMID:32439580 NCBI chr 8:121,590,438...121,598,760
Ensembl chr 8:121,590,361...121,598,760
JBrowse link
G Map2k1 mitogen-activated protein kinase kinase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr 9:64,185,769...64,253,605
Ensembl chr 9:64,185,770...64,253,631
JBrowse link
G Map2k2 mitogen-activated protein kinase kinase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 NCBI chr10:81,105,913...81,124,697
Ensembl chr10:81,105,915...81,133,975
JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 NCBI chr11:110,399,102...110,525,522
Ensembl chr11:110,399,122...110,525,522
JBrowse link
G Mapk1 mitogen-activated protein kinase 1 increases activity
multiple interactions
ISO Glycochenodeoxycholic Acid results in increased activity of MAPK1 protein
[AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of MAPK1 protein]
CTD PMID:21507240, PMID:23300732 NCBI chr16:16,983,382...17,047,453
Ensembl chr16:16,983,382...17,047,453
JBrowse link
G Mapk3 mitogen-activated protein kinase 3 increases activity
multiple interactions
ISO Glycochenodeoxycholic Acid results in increased activity of MAPK3 protein
[AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of MAPK3 protein]
CTD PMID:21507240, PMID:23300732 NCBI chr 7:126,759,626...126,765,816
Ensembl chr 7:126,759,601...126,765,819
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA CTD PMID:32152650 NCBI chr11:49,846,728...49,886,421
Ensembl chr11:49,846,751...49,886,421
JBrowse link
G Mapkapk3 mitogen-activated protein kinase-activated protein kinase 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 NCBI chr 9:107,254,927...107,289,877
Ensembl chr 9:107,254,927...107,289,877
JBrowse link
G Mcl1 myeloid cell leukemia sequence 1 multiple interactions
increases phosphorylation
ISO
EXP
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glycochenodeoxycholic Acid results in increased phosphorylation of MCL1 protein]; [Glycochenodeoxycholic Acid results in increased phosphorylation of MCL1 protein] which results in decreased degradation of MCL1 protein; Glycochenodeoxycholic Acid inhibits the reaction [HUWE1 protein binds to MCL1 protein]
Glycochenodeoxycholic Acid results in decreased expression of and results in increased degradation of MCL1 protein; lysophosphatidylethanolamine analog inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of and results in increased degradation of MCL1 protein]
CTD PMID:21507240, PMID:25125499 NCBI chr 3:95,656,944...95,663,179
Ensembl chr 3:95,658,788...95,663,176
JBrowse link
G Mgst2 microsomal glutathione S-transferase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 NCBI chr 3:51,636,912...51,682,675
Ensembl chr 3:51,660,360...51,682,677
JBrowse link
G Mlkl mixed lineage kinase domain-like multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 NCBI chr 8:111,311,255...111,338,479
Ensembl chr 8:111,311,797...111,338,177
JBrowse link
G Nos2 nitric oxide synthase 2, inducible increases expression ISO Glycochenodeoxycholic Acid results in increased expression of NOS2 mRNA CTD PMID:15767249 NCBI chr11:78,920,787...78,960,226
Ensembl chr11:78,920,787...78,960,254
JBrowse link
G Nos3 nitric oxide synthase 3, endothelial cell decreases expression
multiple interactions
ISO Glycochenodeoxycholic Acid results in decreased expression of NOS3; Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA; Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein
[Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein] which results in decreased abundance of Nitric Oxide; Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA]; Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein]; Calcimycin inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA]; Ubiquinone inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA]; Ubiquinone inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein]; Ubiquinone inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3]
CTD PMID:19837105, PMID:20020783 NCBI chr 5:24,364,816...24,384,474
Ensembl chr 5:24,364,810...24,384,474
JBrowse link
G Nqo1 NAD(P)H dehydrogenase, quinone 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA CTD PMID:32152650 NCBI chr 8:107,388,225...107,403,205
Ensembl chr 8:107,388,225...107,403,206
JBrowse link
G Nqo2 N-ribosyldihydronicotinamide quinone reductase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr13:33,964,655...33,988,465
Ensembl chr13:33,964,687...33,988,443
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA CTD PMID:32152650 NCBI chr10:89,454,234...89,533,645
Ensembl chr10:89,454,234...89,533,585
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA CTD PMID:32152650 NCBI chr16:38,248,349...38,294,849
Ensembl chr16:38,248,323...38,294,824
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA CTD PMID:32152650 NCBI chr 1:171,213,934...171,218,845
Ensembl chr 1:171,213,970...171,220,701
JBrowse link
G Parp1 poly (ADP-ribose) polymerase family, member 1 increases cleavage EXP Glycochenodeoxycholic Acid results in increased cleavage of PARP1 protein CTD PMID:25125499 NCBI chr 1:180,568,891...180,600,999
Ensembl chr 1:180,568,924...180,601,254
JBrowse link
G Pik3c2b phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr 1:133,045,672...133,108,691
Ensembl chr 1:133,045,667...133,108,687
JBrowse link
G Pik3c2g phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 NCBI chr 6:139,614,072...139,969,284
Ensembl chr 6:139,587,221...139,969,284
JBrowse link
G Pik3c3 phosphatidylinositol 3-kinase catalytic subunit type 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:30,265,615...30,348,126
Ensembl chr18:30,272,747...30,348,126
JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr13:101,680,761...101,768,217
Ensembl chr13:101,680,563...101,768,217
JBrowse link
G Rala v-ral simian leukemia viral oncogene A (ras related) multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr13:17,880,575...17,944,217
Ensembl chr13:17,880,571...17,944,239
JBrowse link
G Rap1a RAS-related protein 1a multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 3:105,727,260...105,801,394
Ensembl chr 3:105,727,267...105,801,336
JBrowse link
G Ripk1 receptor (TNFRSF)-interacting serine-threonine kinase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr13:34,002,225...34,035,170
Ensembl chr13:34,002,363...34,037,147
JBrowse link
G Rras2 related RAS viral (r-ras) oncogene 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr 7:114,046,782...114,117,781
Ensembl chr 7:114,046,782...114,117,781
JBrowse link
G Scarb1 scavenger receptor class B, member 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA CTD PMID:32152650 NCBI chr 5:125,277,087...125,341,094
Ensembl chr 5:125,277,087...125,341,094
JBrowse link
G Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA CTD PMID:32152650 NCBI chr 5:137,061,504...137,072,272
Ensembl chr 5:137,061,504...137,072,268
JBrowse link
G Sh3glb1 SH3-domain GRB2-like B1 (endophilin) multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 3:144,683,665...144,720,408
Ensembl chr 3:144,683,678...144,720,335
JBrowse link
G Slc10a1 solute carrier family 10 (sodium/bile acid cotransporter family), member 1 increases uptake
multiple interactions
ISO SLC10A1 protein results in increased uptake of Glycochenodeoxycholic Acid
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA
CTD PMID:29024779, PMID:32152650 NCBI chr12:80,953,185...80,968,705
Ensembl chr12:80,953,183...80,968,705
JBrowse link
G Slc51a solute carrier family 51, alpha subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid]; troglitazone sulfate inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid] CTD PMID:32152650, PMID:32294204 NCBI chr16:32,475,578...32,487,879
Ensembl chr16:32,474,504...32,487,879